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Glioblastoma (GBM) stem cells (GSCs) represent tumor-propagating cells with stem-like 
characteristics (stemness) that contribute disproportionately to GBM drug resistance and tumor 
recurrence.  Understanding the mechanisms supporting GSC stemness is important for 
developing novel strategies that target tumor propagation to inhibit cancer progression and 
improve patient survival. Krüppel-like factor 9 (KLF9) has emerged as a regulator of cell 
differentiation, neural development, and oncogenesis; however, the molecular basis for KLF9’s 
diverse contextual functions has been unclear. We establish for the first time a genome-wide map 
of KLF9-regulated targets in human glioblastoma stem-like cells, and show that KLF9 functions 
as a transcriptional repressor and thereby regulates multiple signaling pathways involved in 
oncogenesis and regulation of cancer stem-like phenotype. A detailed analysis of two novel 
KLF9 targets suggests that KLF9 inhibits glioma cell stemness by repressing expression of 
integrin α6 and CD151. 
 The expression of one candidate KLF9 target gene ITGA6 coding for integrin α6 was 
verified to be downregulated by KLF9 in GSCs. ITGA6 transcription repression by KLF9 altered 
GBM neurosphere cell behavior as evidenced by reduced cell adhesion to and migration through 
membrane coated with the integrin α6 ligand laminin. Forced expression of integrin α6 partially 
rescued GBM neurosphere cells from the differentiating and adhesion/migration-inhibiting 
effects of KLF9.   
Using GBM derived neurospheres, we identified cell surface tetraspanin family member 
CD151 as a novel regulator of GSC stemness and tumorigenicity. CD151 was found to be 
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overexpressed in GBM tumors and GBM neurospheres enriched in GSCs. Silencing CD151 
inhibited neurosphere self-renewal and cell proliferation and attenuated expression of stem cell 
markers and drivers. Conversely, forced CD151 expression promoted neurosphere self-renewal, 
cell migration and expression of stemness-associated transcription factors. Additionally, 
targeting CD151 inhibited glioma angiogenesis and growth of GBM neurosphere derived 
xenografts. CD151 was found to form complexes with integrins α3, α6 and β1 in neurosphere 
cells and blocking the CD151-intgerin α3/α6 interaction impaired sphere formation, migration 
and phosphorylation of AKT, a marker of integrin signaling. These findings identify CD151 and 
its interactions with integrins α3 and α6 as potential therapeutic targets for depleting stem cell 
populations and stemness-driving mechanisms in GBM. 
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Chapter 1: Introduction 
1.1 Glioblastoma Multiforme 
Approximately 70% of malignant primary brain tumors are gliomas. The most 
common glioma is glioblastoma multiforme (GBM), which makes up 50-70% of 
malignant brain tumors. GBM, or glioblastoma, is a grade IV astrocytoma and is the most 
aggressive primary brain tumor (Alifieris & Trafalis, 2015). There are two clinical GBM 
subtypes: primary and secondary (Ahmed, Oborski, Hwang, Lieberman, & Mountz, 
2014). A majority (95%) of GBMs are primary tumors, which arise de novo, within 3-6 
months. These tumors are highly aggressive, invasive, and typically occur in older 
patients. Secondary GBMs are less common and evolve from the progression of lower-
grade astrocytomas (over 10-15 years). These typically occur in patients less than 45 
years old (Crespo et al., 2015). GBMs can be further divided into four molecular 
subtypes: classical, mesenchymal, proneural and neural. These subtypes are distinguished 
by different mutation and transcriptional patterns and can also differ in patient survival, 
patient age and sensitivity to treatment (Verhaak et al., 2010).   
 Each year, 2-3 cases of GBM per 100,000 adults and 1.1 to 3.3 cases per 100,000 
children are reported in the United States and Europe. Males are more likely to develop 
the disease, with the incidence being 3 times higher in male children than female children 
(Urbanska, Sokolowska, Szmidt, & Sysa, 2014). Patients with GBM may experience 
headaches, vomiting, blurred vision, neurological deficits, memory loss, variations in 
personality or seizures (Alifieris & Trafalis, 2015). The current standard of treatment for 
newly diagnosed patients under 70 years of age is surgical resection followed by 
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radiotherapy and chemotherapy. Despite this aggressive treatment, recurrence is often 
seen. Patients with GBMs typically have a median survival time of only 12-15 months 
following treatment (Alifieris & Trafalis, 2015; Dolecek, Propp, Stroup, & Kruchko, 
2012; McGirt et al., 2009). 
GBMs are typically located in the cerebral hemispheres, the brain stem or the 
cerebellum (Figure 1.1). They are composed of a heterogeneous, anaplastic population of 
small abnormal shaped cells, that also display a high nuclear to cytoplasmic ratio 
(Urbanska et al., 2014). GBMs also display some degree of necrosis.  Primary tumors 
typically have a large area of necrosis in the center of the tumor due to insufficient blood 
supply. Smaller irregularly shaped necrotic foci surrounded by hypercellular zones called 
pseudopalisades are found in both primary and secondary tumors. Additionally, GBM is 
one of the most highly vascularized tumors. The tumor vessels are highly permeable with 
abnormal endothelial walls and discontinuous pericyte coverage(Soda, Myskiw, Rommel, 
& Verma, 2013).  
 Activation of several signaling pathways is altered in GBM resulting in the 
support of brain tumor growth and progression.  The three most prominent signaling 
pathways that are altered include growth factor tyrosine kinase 
receptor/Ras/phosphatidylinositol 3-kinase (PI3K)/ phosphatase and tensin homolog 
(PTEN)/Akt pathways (Alentorn et al., 2012; Dasari et al., 2010; Fan et al., 2002; P. H. 
Huang, Xu, & White, 2009; Koul, 2008; Patil et al., 2013; Rajasekhar et al., 2003), the 
P53 (Zawlik, Kita, et al., 2009) pathway and the RB tumor suppressor pathways (Cancer 
Genome Atlas Research, 2008) (Figure 1.2). In addition to genetic changes, epigenetic 
changes have also been associated with GBM. These include MGMT promoter 
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methylation (Zawlik, Vaccarella, et al., 2009), hypermethylation of CpG islands , and 





Figure 1.1 Preoperative (A) axial and (B) coronal post-contrast MR images of a 78-





Figure 1.2 Frequent genetic alterations in three major signaling pathways in GBM. 
(A-C) Alterations for components of the (A) RTK/RAS/PI(3)K, (B) p53 and (C) RB 
signaling pathways are shown. Red indicates activating genetic alterations, with 
frequently altered genes shown in dark red. Blue indicates inactivating alterations, with 
genes with a higher percentage of alteration shown in dark blue. For each altered 
component of a particular pathway, the type of the alteration and the percentage of 
tumors affected are indicated. The boxes show the total percentages of glioblastomas 
with alterations in at least one known component gene of the pathway (Cancer Genome 
Atlas Research, 2008).   
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1.2 Cancer Stem Cells 
Tumors consist of heterogeneous cells. There are two theories as to how this 
heterogeneity arises: the stochastic model and the cancer stem cell model (Figure 1.3).  
The stochastic model predicts that all cancer cells have the potential to form tumors, and 
the variability in their tumorigenicity is determined by stochastic intrinsic factors.  The 
cancer stem cell model predicts that there is a minority population of cancer cells capable 
of propagating tumors. These cells give rise to the bulk of the tumor cells, which have 
limited tumorigenic potential and display a more differentiated phenotype (Nguyen, 
Vanner, Dirks, & Eaves, 2012). 
Progression of several tumor types, including GBMs, is thought to be driven by 
cancer stem cells (CSCs). These highly tumorigenic cells display stem cell properties (i.e. 
stemness), including the ability to self-renew as spheres and the capacity to differentiate 
into the multiple lineages that make up the tumor population (Ajani, Song, Hochster, & 
Steinberg, 2015; Lobo, Shimono, Qian, & Clarke, 2007). Most importantly, CSCs 
efficiently propagate tumor xenografts that recapitulate the biological and 
histopathological characteristics of its original tumor when implanted orthotopically 
(Visvader & Lindeman, 2008). These cells use microenvironment-dependent and 
independent mechanisms to promote tumor angiogenesis, recurrence and resistance to 
cytotoxic therapies (Bao et al., 2006; L. Hu, McArthur, & Jaffe, 2010; Phillips, McBride, 
& Pajonk, 2006; Sarvi et al., 2014; Warrier, Pavanram, Raina, & Arvind, 2012; L. Zhang 
et al., 2012) and have a higher tendency to metastasize (Nakamura, Iinuma, Aoyagi, 





Figure 1.3. Models of cancer cell heterogeneity. (A) In the stochastic model, tumor 
cells have varying tumorigenic potential, which depends on stochastic intrinsic factors. 
(B) In the cancer stem cell model, only a subset of cancer cells (cancer stem cells) has the 
potential to give rise to other cancer stem cells and to cells with a more limited 




The History of Cancer Stem Cells 
The idea of stem cells contributing to cancer development was initially 
formulated in 1907 by Max Askanazy. He developed the “embryonic rest hypothesis of 
cancer development” which postulates that cancers arise from embryo-like cells. The first 
evidence of stem cells arose in 1961 when Ernest McCulloch found that a subset of 
hematopoietic cells could give rise to colonies of cells following irradiation (Till & Mc, 
1961).  Evidence of CSCs was revealed soon after in a study by Bruce and Van Der Gaag 
(1963) that found that a subset of mouse lymphoma cells are able to form colonies in the 
spleen of mice. In 1971, Pierce and Wallace provided evidence of a cellular hierarchy in 
tumors that showed that only the undifferentiated cells give rise to the differentiated 
tumor cells in squamous cell carcinomas suggesting that tumor growth is dependent on 
undifferentiated cell proliferation. Hamburger and Salmon (1977) also found that only a 
minority of epithelial tumor cells could form colonies in vitro.   
However, the first compelling evidence of cancer stem cells was provided in a 
study by Bonnet and Dick (1997) that identified and characterized a subset of cells 
capable of initiating human acute myeloid leukemia in mice with severe combined 
immunodeficiency (SCID).  Since then, cancer stem cells have been discovered in several 
different cancers including breast, brain, colon, lung and liver (Al-Hajj, Wicha, Benito-
Hernandez, Morrison, & Clarke, 2003; Ignatova et al., 2002; O'Brien, Pollett, Gallinger, 
& Dick, 2007). 
The Cancer Stem Cell Niche 
Both normal cells and cancer stem cells rely on a dynamic microenvironment 
detaining neighboring cells, proteins and other factors to support and maintain their 
9 
 
population. In the CSC niche, CSCs are anchored to the microenvironment through 
interactions between the extracellular matrix (ECM) and adhesion proteins on the cell 
surface. This interaction brings the CSCs in close proximity to factors released by the 
ECM that maintain the stem cell phenotype (Lu, Weaver, & Werb, 2012).   The ECM 
also supports the CSC population by serving as a physical barrier for chemotherapeutics 
and migrating immune cells (Wong & Rustgi, 2013). Additionally, the mechanical 
properties of the ECM can influence stem cell characteristics and behavior. For example, 
a stiff ECM enhances hepatocellular carcinoma cell (HCC) proliferation by stimulating 
hepatocyte growth factor-dependent mitogenic signals through activation of  extracellular 
signal-regulated kinase, protein kinase B (PKB/Akt), and signal transducer and activator 
of transcription 3 (Schrader et al., 2011).   
In addition to the ECM, a variety of cells are recruited to the CSC 
microenvironment to sustain the stem cell population. One such cell, the mesenchymal 
stem cell (MSC), homes to the stem cell niche and releases cytokines that support CSC 
functions in several cancers including breast cancer and ovarian carcinoma. MSCs also 
promote tumorigenesis by supporting cell proliferation, metastasis and angiogenesis 
(Cuiffo & Karnoub, 2012). Endothelial cells also secrete factors that support stem cell 
self-renewal, proliferation and survival (Krishnamurthy et al., 2010; Xu, Wu, & Zhu, 
2013). Tumor-associated macrophages (TAM) in the stem cell niche promote 
chemoresistance and metastasis in tumor cells, and may also promote angiogenesis and 
invasion (Solinas et al., 2010). 
The tumor microenvironment also produces several cytokines and factors that 
promote CSC self-renewal, stimulate angiogenesis and recruit cells that support CSC 
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maintenance and tumor progression. For example, exogenous vascular endothelial growth 
factor (VEGF) stimulates glioblastoma stem cell (GSC) proliferation by activating VEGF 
receptor (VEGFR) 2 (Xu et al., 2013). Transforming growth factor β (TGF-β) induces 
epithelial–mesenchymal transition (EMT), a process that has been shown to enhance 
stemness characteristics and tumorigenicity in cancer cells, and tumor invasion and 
metastasis (Smith, Robin, & Ford, 2012; Ye et al., 2012).  
 There is increasing evidence that CSCs are supported by hypoxic tumor 
microenvironments as well. Hypoxia increases expression of hypoxia-induced factors 
(HIFs), which regulate several genes that regulate adaptation to low oxygen (J. W. Kim, 
Tchernyshyov, Semenza, & Dang, 2006). Additionally, HIFs have been shown to support 
GSC self-renewal, proliferation and survival (Z. Li et al., 2009).  HIFs also support tumor 
angiogenesis and progression and enhance EMT phenotype (Gammon, Biddle, Heywood, 
Johannessen, & Mackenzie, 2013).   
Cancer Stem Cell Markers and Regulators 
While there is no one protein that is exclusively expressed in all CSCs, there are 
proteins that are highly expressed in CSCs, and isolation using these markers can enrich 
for CSCs.  One of the most widely used cell surface markers for CSCs is CD133. It is 
present in several cancers including breast, prostate, pancreas, lung and glioblastoma 
(Grosse-Gehling et al., 2013).  Other potential markers are drivers of cell stemness. 
OCT4, NANOG and SOX2 are three transcription factors involved in reprogramming 
somatic cells into induced pluripotent stem cells. In embryonic stem cells (ESCs), these 
transcription factors maintain stem cell self-renewal and pluripotency while also 
inhibiting differentiation (A. Liu, Yu, & Liu, 2013). These transcription factors are 
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upregulated in many cancers, particularly in poorly differentiated tumors, and have been 
shown to contribute to CSC regulation (Ben-Porath et al., 2008; Chiou et al., 2008).  For 
example, NANOG promotes tumor formation and clonogenic capacity in prostate and 
colorectal CSCs and increases chemoresistance in breast cancer cell lines (Ibrahim et al., 
2012; Jeter et al., 2011; J. Zhang et al., 2013). OCT4 increases tumorsphere formation, 
stem cell marker expression and tumorigenicity in mouse breast cancer cells (R. J. Kim & 
Nam, 2011). SOX2 was identified as a CSC marker in skin squamous cell carcinoma and 
medulloblastoma (Becher & Holland, 2014) and regulates self-renewal, chemoresistance 
and tumorigenicity in head and neck squamous cell carcinoma and melanoma-initiating 
cells (S. H. Lee et al., 2014; Santini et al., 2014). 
Because CSCs and normal stem cells share phenotypic properties, it is not 
unexpected that they also share signaling pathways that maintain their stemness and 
regulate their tumor propagating capacity. These include the Notch (Lagadec et al., 2013; 
Suman, Das, & Damodaran, 2013), Wnt/β catenin (Clevers, Loh, & Nusse, 2014; Lobo et 
al., 2007), JAK/STAT (Bourguignon, Earle, Wong, Spevak, & Krueger, 2012; Kroon et 
al., 2013; L. Lin et al., 2011; Torres & Watt, 2008) and Sonic Hedgehog (SHH) pathways 
(Clement, Sanchez, de Tribolet, Radovanovic, & Ruiz i Altaba, 2007; F. T. Huang et al., 
2012; Sims-Mourtada et al., 2006). 
Culturing and Isolating Cancer Stem Cells 
CSCs are grown in specialized cell culture conditions without serum and in the 
presence of growth factors. Traditionally, cancer stem cells, specifically GSCs, were 
grown as adherent cultures in the presence of serum. However, unlike in GBM patients, 
these cells were not invasive in xenograft models. These cells also expressed a high level 
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of differentiation markers. In 1992, Reynolds and Weiss  discovered that neural stem 
cells (NSCs) could be expanded as free-floating neurospheres in specialized, serum-free 
culture medium containing specific growth factors. Soon after, it was discovered that cell 
isolates from GBMs also form spheres consisting of stem and non-stem cells in similar 
medium conditions Ignatova et al. (2002). 
Glioblastoma Stem Cells 
Glioblastoma stem cells (GSCs), or GBM-propagating cells, were first identified 
by Ignatova et al. (2002) in a study that found that glial tumor cells could form colonies 
in anchorage and serum free conditions in the presence of growth factors. Similar to 
neural stem cells (NSCs), GSCs form neurospheres and have the ability to self-renew as 
spheres. Unlike NSCs, GSCs have several genetic alterations, are chemoresistant and 
radioresistant and can recapitulate the original tumor in in vivo xenografts (Goffart, 
Kroonen, & Rogister, 2013). Although a universal marker for GSCs has not been 
identified, CD133 is most commonly used. Several other candidates have been identified 
including A2B5, CD44, L1CAM, SSEA1, integrin α6, Musashi, Nestin, Nanog, Oct4 and 
Sox2 (Sundar, Hsieh, Manjila, Lathia, & Sloan, 2014).   
The origin of GSCs is still relatively unknown. There are two hypotheses that are 
currently supported: the dedifferentiation hypothesis and the stem cell hypothesis. The 
dedifferentiation hypothesis proposes that mature astrocytes accumulate genetic 
alterations over time that promote anchorage independent growth, resistance to 
antigrowth signals and apoptosis and self-renewal, resulting in malignant transformation 
of these cells(Bachoo et al., 2002; Uhrbom et al., 2002).  
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The stem cell theory proposes that GSCs arise from NSCs and progenitor cells in 
the subventricular zone stem cell niche and other germinal zones in the brain (Goffart et 
al., 2013; Lee da, Gianino, & Gutmann, 2012).  These cells have been shown to 
accumulate mutations leading to tumor formation (Y. Wang et al., 2009). NSCs are also 
preferentially targeted by human cytomegalovirus, a brain tumor promoter (Price et al., 
2013). There is also evidence to suggest that oligodendrocyte progenitor cells (OPCs) 
could potentially give rise to malignant gliomas (Goffart et al., 2013; Lindberg, 
Kastemar, Olofsson, Smits, & Uhrbom, 2009).  
GSCs primarily reside in the brain tumor perivascular niche (PVN), located along 
the border of the tumor vasculature. The PVN is made up of several tumor and non-tumor 
cells including pericytes, macrophages, astrocytes and endothelial cells. Pericytes support 
the integrity of the tumor vascular and may contribute to microvascular proliferation in 
the tumor (Bababeygy et al., 2008; Guo et al., 2003). Macrophages in the brain, or 
microglia, are recruited to the perivascular niche by GSCs to support tumor growth. 
These cells localize to the advancing edge, the perivascular niche and perinecrotic 
regions to promote cell motility, metastasis and angiogenesis, respectively (Lewis & 
Pollard, 2006).  Astrocytes contribute to GSC regulation by secreting factors such as 
SHH and astrocyte elevated gene-1 to support GSC self-renewal, invasion and survival 
(Charles & Holland, 2010; Emdad et al., 2010). Endothelial cells provide nutrients, 
oxygen and diffusible factors, such as eNOS, that regulate stem cell self-renewal and 
proliferation (Charles & Holland, 2010). GSCs in turn support the perivascular niche by 
secreting high levels of VEGF which results in highly angiogenic tumors. GSCs also 
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induce endothelial cell proliferation, migration and tube formation (Charles & Holland, 
2010). 
Multiple signaling pathways are active and support the PVN, like the SHH 
signaling pathway. SHH expression localizes to the glioma PVN and correlates with 
glioma grade (Becher et al., 2008). Inhibition of SHH pathway members Gli1 and SMO 
has also been shown to reduce glioma cell proliferation, migration and invasion (Clement 
et al., 2007; K. Wang, Pan, Che, Cui, & Li, 2010). The PI3K/Akt pathway, in addition to 
contributing to tumor formation and growth, supports GSC drug resistance in the PVN 
(Hambardzumyan et al., 2008; Holland et al., 2000). Notch signaling in GSCs has also 
been shown to regulate PVN angiogenesis (Charles & Holland, 2010). 
Another GSC niche in GBMs are perinecrotic regions within the tumor with 
activated HIF1α and HIF2α, the main mediators of the hypoxic response (Seidel et al., 
2010). HIF proteins are stabilized in hypoxic conditions and bind to hypoxia responsive 
elements on promoters of genes involved in cell survival, motility, metabolism and 
angiogenesis. HIF1α promotes proliferation and survival of all cancer cells while HIF2α 
enhances transcription in GSCs to promote GSC self-renewal and tumorigenicity 
(Covello et al., 2006; Heddleston, Li, McLendon, Hjelmeland, & Rich, 2009; Z. Li et al., 
2009; Seidel et al., 2010). 
1.3 Krüppel-like Factors and KLF9 
Krüppel-like Factors 
The krüppel-like factors (KLFs) compose a family of transcription factors that 
bind to GC rich regions of DNA to activate or repress transcription. The first human KLF 
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was identified by Page et al. in 1987. The first mammalian klf gene was cloned soon after 
in 1993 (I. J. Miller & Bieker). Since then, 16 other mammalian KLFs have been 
identified and are designated KLF1-KLF17 (Suske, Bruford, & Philipsen, 2005). 
KLFs have three highly conserved consecutive Cys2-His2 zinc fingers located near 
the carboxyl terminus of the protein that enables them to interact with GC-rich sequences 
in target gene promoters and enhancers (Pearson, Fleetwood, Eaton, Crossley, & Bao, 
2008). However, they have unique amino-terminal sequences that permit the transcription 
factors to interact with specific binding partners (McConnell & Yang, 2010) (Figure 1.4). 
Through transcriptional regulation of a variety of genes, KLFs regulate numerous cellular 





Figure 1.4 Structure of KLFs. KLFs consists of three C-terminal finger domains, each 
consisting of two cysteine and two histidine residues chelating one zinc ion. The zinc 
fingers are connected by a “TGERP”-like motif which assist DNA binding. The more 
variable activation/repression domain is found at the N-terminus of the molecule and 
determines the activating function of the transcription factor (Pearson, Fleetwood, Eaton, 




KLFs are also involved in cell differentiation. For example, KLF1 supports 
erythropoiesis and regulates megakaryocyte-erythroid progenitor differentiation into 
erythrocytes (Drissen et al., 2005; McConnell & Yang, 2010). Several KLFs (KLFs 2, 3, 
4, 5, 6, 7, 11, and 15) are involved in adipogenesis (McConnell & Yang, 2010). There is 
also evidence of KLF regulation of differentiation of cardiomyocytes, corneal epithelial 
cells and many other tissues (C. M. Carlson et al., 2006; Kuo et al., 1997; Nemer & Horb, 
2007; Swamynathan et al., 2007).   
 Some KLFs support the self-renewal of stem cells. KLF4 is one of four 
transcription factors rigourously described by Yamanaka that, when ectopically 
expressed, reprogram somatic cells to pluripotent stem cells (Takahashi & Yamanaka, 
2006; Wernig et al., 2007). Depletion of KLFs 2, 4 and 5 has also been shown to result in 
embryonic stem cell differentiation (Jiang et al., 2008).  
KLFs may function as tumor suppressors and/or oncogenes depending on the 
cellular context. For example, KLF4 functions as a tumor suppressor by regulating cell 
cycle promoting genes in colon cancer (Rowland, Bernards, & Peeper, 2005). KLF6 
functions as a tumor suppressor that is mutated in prostate and/or suppressed in many 
other cancers (McConnell & Yang, 2010; Narla et al., 2001). KLF8 expression is 
increased in many cancers and tissues and aberrant expression induces transformation (X. 
Wang & Zhao, 2007).  
KLFs have also been implicated in CSCs. Most notable is KLF4. Knockdown of 
KLF4 in breast cancer cell lines reduces the cancer self-renewal capacity and the CSC 
population (F. Yu et al., 2011). KLF4 is also overexpressed in the CSC subpopulation in 
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colon cancer, and KLF4 silencing decreases the chemoresistance, invasion and 
tumorigenicity of these cells (Leng et al., 2013). Knockdown of KLF5 in ovarian CSCs 
increases the sensitivity of these cells to chemotherapeutics (Z. Dong, Yang, & Lai, 
2013).  
Krüppel-like Transcription Factor 9 
KLF9 was isolated in 1992 from rat cDNA libraries (Imataka et al.). Its cDNA 
clone consists of 244 amino acids. (Ohe et al., 1993). KLF9’s RNA was detected in every 
organ examined suggesting that it plays a fundamental role in cells. However, it was most 
abundant in the kidney, lung, brain and testis (Imataka et al., 1992). KLF9 binds to the 
basic transcription element (BTE) (Yanagida, Sogawa, Yasumoto, & Fujii-Kuriyama, 
1990). Although it primarily functions as a transcriptional repressor, KLF9 has been 
shown to have both activating and repressive regulatory functions on gene transcription. 
However, this may depend on the number of GC boxes present. For example in monkey 
cell line CV-1, KLF9 functioned as a transcriptional repressor when BTE, a sequence 
consisting of a single GC box consensus sequence and part of the NF-1 binding sequence 
(Yanagida et al., 1990), but served as an activator when tandem repeats of the GC boxes 
were present (Imataka et al., 1992). 
KLF9 regulates a variety of cellular functions, including survival and proliferation 
(Savignac et al., 2010; X. L. Zhang, Simmen, Michel, & Simmen, 2001; Zucker et al., 
2014). However, it is best known for its role in steroid hormone signaling. KLF9 forms a 
complex with progesterone receptor (PR) B to promote transactivation of progresterone-
responsive genes to ligand bound PR (D. Zhang et al., 2002).  KLF9 also functions as a 
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negative regulator of estrogen receptor α signaling (Pabona, Velarde, Zeng, Simmen, & 
Simmen, 2009; Velarde, Zeng, McQuown, Simmen, & Simmen, 2007).  
KLF9 has also been shown to regulate cell differentiation. For instance, KLF9 is 
upregulated following differentiation of dental follicle cells, preadipocytes and 
keratinocytes (Kimura & Fujimori, 2014; Morsczeck et al., 2009; Sporl et al., 2012). 
Mice null for KLF9 have shorter villi, inhibited cell proliferation and an alteration in the 
lineage determination in the intestines (Simmen et al., 2007).  
KLF9 particularly influences differentiation in the central nervous system. KLF9 
contributes to late phase maturation of dentate granule neurons, evidenced by the fact that 
loss of KLF9 inhibited late phase processes. Adult-born neurons in KLF9-null mice have 
fewer mature neurons and fewer neurons with complex dendritic trees (Scobie et al., 
2009). Expression of KLF9 increases in the brain during tadpole metamorphosis and is 
expressed just outside of proliferative regions of the brain, supporting a role in neural cell 
differentiation (Hoopfer, Huang, & Denver, 2002). KLF9-/- mice also exhibit deficits in 
the rotating rod test and contextual freezing response behavioral tests compared to 
wildtype mice, which suggests deficits in the cerebellum, hippocampus and the 
amygdala, respectively (Morita et al., 2003).  
Several studies point to KLF9 functioning as a tumor suppressor. KLF9 is 
downregulated in several cancers including colorectal cancer, non-small cell lung cancer, 
esophageal squamous cell carcinoma (ESSC), hepatocellular carcinoma, prostate cancer, 
endometrial and breast cancer (Kang, Lu, Xu, Hu, & Lai, 2008; Qiao et al., 2015; Tong, 
Liu, Wang, Zhang, & Liu, 2015). Forced expression of KLF9 inhibits cell growth, 
migration and metastasis of ESCC and HCC cells (Fu, Cheng, He, Liu, & Liu, 2014; 
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Qiao et al., 2015; Sun et al., 2014), delays tumor formation from HCC and prostate 
cancer cells and promotes regression of tumors established from HCC cells (P. Shen et 
al., 2014; Sun et al., 2014). However, KLF9 has been shown to promote tumor 
progression in ovarian cancer (Q. H. Zhang, Dou, Tang, Su, & Liu, 2015). 
KLF9 and Glioma Stem Cells 
KLF9 expression is downregulated in glioma cell lines and tissues, particularly 
grade III astrocytoma and GBM, compared to astrocyte cells and normal brain tissue, 
respectively (S. Huang et al., 2015). We previously showed that KLF9 expression is 
induced during forced differentiation of GSCs. Knockdown of KLF9 inhibits forced 
differentiation of GSCs while forced expression of KLF9 inhibits cell proliferation, 
sphere formation, invasion and tumor formation (Ying et al., 2011). Consistent with what 
we found, S. Huang et al. (2015) showed that knockdown of KLF9 increased glioma cell 
proliferation while its forced expression inhibited proliferation and glioma cell 
tumorigenicity. We found that KLF9 regulates GSC self-renewal in part by binding to the 
promoter of Notch1 and suppressing Notch signaling (Ying et al., 2011). However, other 
target genes and the molecular mechanism underlying KLF9’s functional contribution to 
differentiation had yet to be comprehensively identified.  
In the present study, we determined global KLF9 gene-binding and transcriptional 
signatures in human GBM-derived neurospheres using chromatin immunoprecipitation 
followed by high throughput deep sequencing (ChIP-Seq) and RNA-sequencing. This 
combined approach revealed a significant role for KLF9 in the regulation of several 
pathways involved in oncogenesis and stem cell biology, including the integrin signaling 
pathway. A more in depth analysis of proteins encoded by KLF9 gene targets integrin α6 
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and CD151 reveal novel mechanisms by which KLF9 regulates glioblastoma cell 
stemness.  
1.4 Integrins and Integrin α6 
Integrins 
Integrins, a family of cell adhesion receptors, were discovered in multiple species 
and cell types and given various names in the 1980s (Hemler, Jacobson, & Strominger, 
1985; Horwitz, Duggan, Greggs, Decker, & Buck, 1985; Knudsen, Horwitz, & Buck, 
1985; Tamkun et al., 1986). It wasn’t until the genes of these proteins were sequenced 
that they were found to be related (Hynes, 2004). Each integrin consists of a heterodimer 
between an α and β subunit that make up extracellular “headpiece” and “leg” regions, 
which pass through the membrane once, terminating in typically short cytoplasmic 






Figure 1.5. Integrin structure. (A) Domain structure and (B) bimolecular structure of 
αxβ2 using the same color coding; (C) cartoon representation of bent (inactive) and 
upright (activated) conformations (Campbell & Humphries, 2011).  
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Integrins are capable of bi-directional signaling. The main function of inside-out 
signaling is to promote the active integrin conformation to enhance binding to 
extracellular ligands. Ligand binding is facilitated by integrin binding proteins, talin and 
kindlins. These proteins promote integrin activation through strong interactions with the 
β integrin cytoplasmic tail (P. Hu & Luo, 2013). Exposure to ECM ligands stimulates 
integrin clustering to strengthen the high affinity integrin conformation. This increases 
ligand binding and triggers outside in signaling. Integrin clustering leads to the formation 
of small dynamic adhesions that can dissipate or develop into larger more stable focal 
adhesions. Both integrin α and β tails recruit focal adhesion kinase (FAK), integrin-linked 
kinase and Src family kinase, all of which facilitate the recruitment of other proteins to 
support the focal adhesion. Through this interaction with the ECM, integrins provide cells 
with information about the extracellular environment through downstream signaling 









Integrins are the primary cell surface receptors for adhesion to the ECM and 
activate intracellular signal transduction to regulate cellular processes such as 
cytoskeletal rearrangement, cell polarity, motility and gene expression in response to 
changes in the extracellular environment (Figure 1.6). These receptors have several 
ligands, including major ECM constituents laminin, fibronectin, and collagen (Johnson, 
Lu, Denessiouk, Heino, & Gullberg, 2009).  In addition to ECM proteins, integrins can 
also interact with cell surface receptors on adjacent cells through interactions with 
membrane bound adhesion proteins like vascular or intracellular- cell adhesion molecules 
(VCAM and ICAM) (Prowse, Chong, Gray, & Munro, 2011). 
Integrins detect and convey mechanical forces at the cell-matrix interface to the 
cell’s interior where it is converted into biochemical signals, a process known as 
mechanotransduction. Integrins then link to the cytoskeleton in order to transmit the force 
throughout the cell and reinforce cell adhesion to resist the forces. The receptors reinforce 
cell adhesion by recruiting signaling proteins to form large complexes with the 
cytoskeleton called focal adhesions (DeMali, Sun, & Bui, 2014).  
Mounting evidence is revealing the integrin signaling pathway to be a major 
player in stem cell regulation. Multiple integrins have been identified as potential stem 
cell markers, with integrin α6 being most notable (Seguin, Desgrosellier, Weis, & 
Cheresh, 2015). Integrins are believed to contribute to stem cell self-renewal largely by 
anchoring the cells to the stem cell niche where the cells can receive short range signals 
from the microenvironment and other cells to promote self-renewal. Integrins regulate 
downstream signaling of FAK and PI3K as well as facilitate EGFR, Notch and other 
signaling pathways involved in self-renewal and proliferation (L. S. Campos, Decker, 
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Taylor, & Skarnes, 2006). The receptors may also influence the polarity of cells to 
promote the retention of stem cells in the niche following cell division (Seguin et al., 
2015). 
Integrins have been implicated in tumor progression as well, the most notable 
receptors being integrins αvβ3, αvβ5, αvβ6, α5β1, α6β4, and α4β1. These receptors 
influence tumor maintenance by promoting cancer cell survival through interaction with 
the ECM (Desgrosellier & Cheresh, 2010). In addition to promoting tumor cell migration 
and drug resistance, integrins influence tumor progression by regulating host tissue 
angiogenesis and immune response to cancer (Brooks, Clark, & Cheresh, 1994; 
Friedlander et al., 1995; Garmy-Susini et al., 2005; Taverna et al., 2004). Many integrins 
are also upregulated in cancer stem cells and potentiate the CSC phenotype (Luo et al., 
2009; Samanna, Wei, Ego-Osuala, & Chellaiah, 2006).  
Integrin α6 
One integrin of particular interest in CSC regulation is integrin α6. Integrin α6 
was identified in the late 1980s in a heterodimer with integrin β1 in platelet lysate 
(Hemler, Crouse, Takada, & Sonnenberg, 1988). Similar to other integrins, the integrin 
α6 subunit has a large extracellular domain (991 residues), a short transmembrane 
domain (23 amino acids) and a short cytoplasmic domain (36 amino acids). Integrin α6 
has two splice variants: integrin α6A and α6B (Hogervorst, Kuikman, van Kessel, & 
Sonnenberg, 1991). The α6A is 18 residues shorter than the α6B variant and is capable of 
being phosphorylated. However, both can heterodimerize with both integrin α6 binding 
partners and interact with laminin. Integrin α6 forms complexes with integrin β1 or β4 to 
regulate cell adhesion to laminin in the basement membrane (Aumailley, Timpl, & 
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Sonnenberg, 1990; Jones, Kurpakus, Cooper, & Quaranta, 1991; E. C. Lee, Lotz, Steele, 
& Mercurio, 1992). 
Integrin α6 is expressed in almost every tissue in the adult human. It is most 
highly expressed in the epithelia of various tissues, with the strongest expression in those 
cells adjacent to the basement membrane. While integrin α6 expression is high in nerve 
cells of the developing embryo, it is mainly expressed only in the peripheral neurons and 
weakly in cerebellum neuron cell bodies in the adult suggesting that it may aid in cell 
migration and axonal growth during development (Terpe, Stark, Ruiz, & Imhof, 1994). 
Integrin α6 is overexpressed in numerous cancers including pancreatic, liver, 
prostate, breast and brain cancer and can be associated with poorer clinical outcome 
(Begum et al., 1995; Chung, Bachelder, Lipscomb, Shaw, & Mercurio, 2002; Colombel 
et al., 2012; Kwon et al., 2013; Martin & Jiang, 2014).  Integrin α6 supports several 
different oncogenic activities including cancer cell migration, metastasis, proliferation 
and survival (Colombel et al., 2012; Kwon et al., 2013; Martin & Jiang, 2014) (Chung et 
al., 2002). 
 Integrin α6 is also highly expressed in stem cells and even serves as a marker for 
many stem cells including prostate cells, HSCs and MSCs (Notta et al., 2011; Yamamoto 
et al., 2012; K. R. Yu et al., 2012). Integrin α6 supports these cells by anchoring them to 
the stem cell niche and directly activating mechanisms to potentiate the stem cell 
phenotype. For example NSCs located closest to the brain vasculature express the highest 
level of integrin α6β1 while those furthest away have lower expression; Blocking the 
integrin α6β1 receptor with an integrin antibody in vitro also reduces adhesion of NSCs 
to endothelial monolayer (Q. Shen et al., 2008). Integrin α6 expression promotes sphere 
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and colony formation in mouse and human prostate cells (Lawson, Xin, Lukacs, Cheng, 
& Witte, 2007; Mulholland et al., 2009). Integrin α6 is also enriched in tumor-
propagating cell populations in various cancers including breast, cervical, prostate, colon 
and brain cancer (GBM)  (Bragado et al., 2012; Cariati et al., 2008; Haraguchi et al., 
2013; Lathia et al., 2010; Lopez, Poitevin, Mendoza-Martinez, Perez-Plasencia, & 
Garcia-Carranca, 2012; Yamamoto et al., 2012). Its expression promotes self-renewal and 
tumorigenicity in CSCs (Cariati et al., 2008; Fukamachi et al., 2013; Haraguchi et al., 
2013; Lopez et al., 2012; To et al., 2010).  
 Integrin α6 has been shown to enrich for GSCs and regulate some GSC 
characteristics. In a 2010 study, Lathia et al. (2010) showed that Integrin α6 is 
upregulated and coexpressed with Olig2 and CD133 in GSCs compared to non-stem 
glioma cells. GSCs positive for integrin α6 were more proliferative and had a greater 
capacity to form spheres than integrin α6- cells regardless of CD133 expression. Integrin 
α6 + cells glioma cells also formed tumors more often and in a shorter time frame than 
those with low integrin α6 expression, suggesting that integrin α6 contributes to glioma 
formation.  
Here, we demonstrate KLF9 regulates glioblastoma cell stemness in part by 
inhibiting integrin α6 expression and downstream functions. KLF9 may also influence 
integrin signaling by downregulation of integrin-binding partner and integrin signaling 
facilitator tetraspanin CD151.   
 




Tetraspanins, or the transmembrane 4 superfamily, consist of 33 transmembrane 
proteins in mammals. These proteins have four transmembrane domains, consisting of 
one small extracellular loop (EC1) and one large extracellular loop (LEL or EC2), and 
two typically short (less than 20 amino acids) cytoplasmic N- and C- terminals (Charrin 
et al., 2009) (Figure 1.7).  Tetraspanins are small proteins between 20 and 30 kDa or 204-
355 amino acids. The small extracellular loop consists of fewer than 30 amino acids, 
while the larger extracellular loop has between 76-131 residues (Charrin et al., 2009). 
These proteins are defined by several structural characteristics in the extracellular loops 
and transmembrane domains including disulfide bonds, a CCG motif and 
posttranslational modifications (such as palmitoylation and N-glycosylation). Most 
tetraspanins are expressed in most or all cell types and localize to the cell membrane. 





Figure 1.7. Structure of Tetraspanins. Tetraspanins are four transmembrane domain 
proteins with one small extracellular loop (EC1) and one large extracellular loop (EC2), 
and two typically short cytoplasmic N- and C- terminals. Tetraspanins also harbor 
disulfide bonds and a CCG motif in the EC2 and display posttranslational modifications 




Tetraspanins associate with multiple cell surface receptors and each other, forming 
specific membrane domains known as tetraspanin-enriched microdomains (TEMs). 
Although the total composition of TEMs is still unknown, it is apparent that TEMs 
consist of interactions between tetraspansins and several adhesion molecules (integrins 
and immunoglobulins), transmembrane receptors, enzymes and each other. Some 
tetraspanins (CD9 and CD82) also interact with gangliosides to stabilize interactions with 
integrins and c-Met.  There are several orders of interaction, which can be detected using 
different detergents. The TEM links tetraspanins to several signaling pathways. Due to 
these interactions, tetraspanins influence several processes including oocyte fertilization, 
immune cell and platelet functions and wound healing (Charrin et al., 2009). 
Tetraspanins have also been shown to contribute to tumor growth and metastasis. 
Tetraspanin 8 is upregulated in many cancers (Anami et al., 2015; Berthier-Vergnes et 
al., 2011; Gesierich et al., 2005; Hemler, 2014; Kanetaka et al., 2001) and promotes 
cancer cell migration and tumor growth (Ailane et al., 2014; Anami et al., 2015; Claas et 
al., 1998; Greco et al., 2010; Kanetaka et al., 2001). CD37 is exclusively expressed in 
mature B cells (Robak & Robak, 2014; Schwartz-Albiez, Dorken, Hofmann, & 
Moldenhauer, 1988) and is typically overexpressed in B cell malignancies (Robak & 
Robak, 2014). Targeting CD37 with antibodies induces apoptosis in lymphoma cells and 
leukemia cells and can be more potent than current standards of treatment (Heider et al., 
2011).   
Tetraspanins also play a major role in the maintenance of stem cells.  Many 
biomarkers for mesenchymal stem cells (MSCs) are tetraspanins (CD63, CD81 and 
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CD82) (Al-Nbaheen et al., 2013; D'Ippolito et al., 2004; H. J. Lee, Choi, Min, & Park, 
2009) . Tetraspanin CD9 is abundantly expressed in mouse and human embryonic stem 
cells and maintains the undifferentiated state in mouse ESCs (Cui et al., 2004; Harkness 
et al., 2008; Nagano et al., 2005; Oka et al., 2002). CD81 is expressed in pancreatic stem 
cells (Lin et al., 2006) and regulates haemopoietic stem cell proliferation through 
regulation of the AKT pathway (K. K. Lin et al., 2011). 
CD82 and CD9 also support cancer stem cells. CD82 expression is high in 
leukemia stem cell-like AML cells (CD34+/CD38-) and blocking its expression inhibits 
colony formation, cell adhesion and AML cell engraftment in vivo (Bonardi et al., 2013; 
Nishioka et al., 2013).  In cell lines established from malignant mesothelioma, CD9 is 
highly expressed with other stem cell markers. CD9high cells form more spheroid colonies 
and generate significantly larger xenograft tumors as well (Ghani et al., 2011).  
CD151 
Tetraspanin CD151, previously known as platelet endothelial tetraspanin antigen-
3 (PETA-3) and SF-HT-activated gene 1 (SFA-1) protein, was identified by a 
monoclonal antibody raised against AML in 1991 (Ashman et al.). It was later cloned and 
characterized by Fitter et al. (1995) and Hasegawa et al. (1996), independently. CD151 
has one open reading frame that is 253 amino acids (759 bp) long with a molecular 
weight of 28kDa (Fitter et al., 1995; Hasegawa et al., 1996). In its mature glycosylated 
form, CD151 has a molecular weight of 32kDa and is seen as a doublet in SDS-PAGE 
protein gels (Sincock et al., 1999b).  Multiple splice variants have also been described for 
this protein.  CD151 also has multiple modification sites including a potential N-
glycosylation site located between the third and fourth transmembrane domains and at 
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least four intracellular palmitoylation sites proximal to the transmembrane domains that 
support CD151’s association with other tetraspanins (Fitter, Tetaz, Berndt, & Ashman, 
1995; Hasegawa, Utsunomiya, Kishimoto, Yanagisawa, & Fujita, 1996; X. Yang et al., 
2002).  
CD151 is expressed in virtually every tissue in normal healthy adults, particularly 
in the epithelium. It is highly expressed in vascular endothelium in multiple tissues, 
including specialized endothelium (capillaries of the blood–brain barrier, glomeruli, etc). 
This suggests that it may play a major role in vascular integrity (Sincock, Mayrhofer, & 
Ashman, 1997). CD151 expression is also high in heart, lung, pancreas and prostate 
tissues (Fitter et al., 1995). A very small amount has been detected in brain tissue, despite 
the high expression of CD151 in brain vasculature (Fitter et al., 1995; Sincock et al., 
1997).  
Because CD151 forms multiple secondary interactions with cell surface proteins 
in the tetraspanin-enriched microdomain (TEM), CD151 promotes several cellular 
processes including cell adhesion (Garcia-Lopez, Barreiro, Garcia-Diez, Sanchez-
Madrid, & Penas, 2005; Geary et al., 2008; Palmer et al., 2014), migration (Fei et al., 
2012; Peng et al., 2013; Sincock et al., 1999b; W. Yang et al., 2012), proliferation (Geary 
et al., 2008; W. F. Liu et al., 2011; Novitskaya, Romanska, Dawoud, Jones, & 
Berditchevski, 2010; Peng et al., 2013; W. Yang et al., 2012; Zheng & Liu, 2007a, 
2007b; Zuo et al., 2010), wound healing (Cowin et al., 2006; Wright et al., 2004) and 
vessel formation (W. F. Liu et al., 2011; Peng et al., 2013; Sincock et al., 1999b; Zheng 
& Liu, 2007a, 2007b; Zuo et al., 2010). CD151 influences these processes through 
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activation of many signaling pathways including PI3K/Akt and Ras/Raf/MEK/ERK 
pathways (W. F. Liu et al., 2011; Zheng & Liu, 2007b; Zuo et al., 2010). 
CD151 primarily complexes with laminin-binding integrins in the TEM. CD151 
directly interacts with the α integrin subunits (α3, α6 and α7) through the extracellular 
loop (Hasegawa et al., 2007). Through these interaction, CD151 facilitates outside in 
integrin signaling and enhances integrin-regulated cellular processes including 
proliferation and cell migration and adhesion to laminin (Fei et al., 2012; W. F. Liu et al., 
2011; Sterk et al., 2000; W. Yang et al., 2012; Zuo et al., 2010). 
 Integrin α3 and α6 form strong (Triton X-100 resistant) associations with CD151 
at extracellular site QRD194-196 (Kazarov, Yang, Stipp, Sehgal, & Hemler, 2002). Integrin 
α7 also appears to form a weaker bond with CD151 at this site (Sterk et al., 2002). This 
interaction is critical for CD151-integrin association and integrin signaling. Mutation of 
site QRD194-6 to AAA194-196 decreased the association between CD151 with integrin α3 
and integrin α6 (W. F. Liu et al., 2011; W. Yang et al., 2012) and reduced CD151’s 
ability to promote proliferation, migration and invasion in endothelial and cancer cells 
(Fei et al., 2012; W. F. Liu et al., 2011; Zuo et al., 2010). The mutation also prevented 
activation of integrin signaling pathway proteins FAK, PI3K, Akt, eNOS, ERK1/2, cdc42 
and Rac1 by forced CD151 expression (W. F. Liu et al., 2011). CD151 also interacts with 
tetraspanins CD9 and CD81 in regions of cell-cell contact and has been shown to 
associate with GTPases when CD151 is overexpressed (Blumenthal et al., 2012; Hong, 
Jeoung, Ha, Kim, & Lee, 2012). 
CD151 is highly expressed in several cancers, including gastric, endometrial, 
liver, breast, prostate (Detchokul, Newell, Williams, & Frauman, 2014; Devbhandari et 
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al., 2011; Voss et al., 2011; X. H. Yang et al., 2008; Y. M. Yang et al., 2013). Its aberrant 
expression is associated with multiple oncogenic activities such as metastasis and 
angiogenesis (Deng et al., 2012; Devbhandari et al., 2011).   
CD151 has also been implicated in the progression of high grade glial tumors, 
including GBM. CD151 mRNA levels are consistently upregulated in clinical GBM 
samples (Bredel et al., 2005). Patients with CD151-high glial tumors exhibit shorter 
progression free survival (PFS) and overall survival (OS) (D. Lee et al., 2013). The 
expression of CD151 is also correlated with MGMT promoter methylation status, and its 
predictive potential was improved when combined with MGMT promoter methylation to 
determine OS probability of patients with newly diagnosed GBMs (D. Lee et al., 2013). 
CD151 is also highly expressed in glioblastoma with an oligodendroglial component 
(GBMO), a subgroup of GBMs that display oligodendroglial phenotype in various areas 
throughout the tumor (Ha, Kang, Do, & Suh, 2013). 
Functional analysis of gene expression in glioma tumor samples revealed an 
association of CD151 with glioblastoma cell invasion (Bredel et al., 2005).  This 
association is supported by Rao Malla et al. (2013) who showed that downregulation of 
CD151 and blocking CD151 interaction with integrin α3β1 via silencing of cell surface 
proteins uPAR and Cathepsin reduced glioma cell adhesion and invasion on laminin. 
Not much is known about the role of CD151 in stem cells. There is data 
suggesting that it is associated with less differentiated states in chrondocytes. For 
example, CD151 is highly expressed in MSCs (Diaz-Romero, Nesic, Grogan, Heini, & 
Mainil-Varlet, 2008; H. J. Lee et al., 2009), and the percentage of CD151+ cells 
decreases significantly during MSC differentiation (H. J. Lee et al., 2009). CD151 is also 
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highly expressed in less differentiated cells in oral squamous cell carcinoma tumors. 
(Romanska et al., 2013).  Ablation of CD151 in CD24HiCD49fLow mammary cells, a 
subpopulation of luminal cells enriched in stem and progenitor cells, also increased the 
differentiation potential of progenitor cells and proliferative cells (Yin et al., 2014).  
Very few studies have investigated the role of CD151 in CSCs. CD151 is highly 
expressed in prostate tumor-propagating cells and enhances sphere formation and tumor 
initiation (Rajasekhar, Studer, Gerald, Socci, & Scher, 2011). CD151 is also consistently 
expressed in several CD133+ tumorigenic colon cancer cell lines (Gemei, Di Noto, 
Mirabelli, & Del Vecchio, 2013). 
We investigated the expression and function of CD151, whose gene is also 
downregulated by KLF9, in tumor-initiating GSCs using human GBM–derived 
neurosphere cultures. CD151 was found to be highly expressed in glial tumors and GSC 
lines. CD151 silencing in GSCs blocked self-renewal, migration, xenograft growth and 
vessel formation. CD151 knockdown also increased apoptosis in vivo. CD151 
overexpression enhanced GSC self-renewal and migration. CD151 associated with 
integrins α3, α6 and β1 in GSCs. Blocking CD151 interaction with integrins α3 and α6 
inhibited sphere formation, migration and activation of downstream integrin signaling. 
Together, the results support a critical role for CD151 and CD151-integrin interaction in 




Materials and Methods 
Reagents 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
www.sigmaaldrich.com). Stock of all-trans retinoic acid (RA) was prepared in DMSO 
and diluted to 1µM in cell culture medium as a working concentration. Doxycycline 
(Dox) was diluted to a concentration of 0.5 µg/ml in cell culture medium as a working 
concentration. In all the experiments, the final DMSO concentration was <0.1% and 
DMSO also had no demonstrable effect on neurosphere cultures. Laminin was diluted to 
10 µg/ml as a working concentration. 
 
Cell Culture 
The human glioblastoma neurosphere lines GBM1a (0913) and GBM1b (0627) 
were originally derived, characterized, and shown to be enriched in GSCs by Vescovi and 
colleagues (Galli et al., 2004). The enrichment of GSCs in these neurosphere lines have 
since been validated by multiple other investigators (Y. Li et al., 2011; Ying et al., 2011). 
The 1123 (M1123) and 146 (P146) neurosphere lines were derived from high grade 
glioma patients and kindly provided by Dr. Nakano (Ohio State University). Primary 
GBM neurospheres JHH612 (612) were derived from clinical GBM specimens at Johns 
Hopkins University using the methods and culture conditions described by Galli et al. 
(2004). Neurospheres were cultured and maintained in serum-free medium supplemented 
with epidermal growth factor (EGF) and fibroblast growth factor (FGF), and incubated in 
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a humidified incubator containing 5% CO2/95% air at 37 °C and passaged every 4–5 
days by mechanical dissociation as described by Vescovi et al. and others (Galli et al., 
2004; Sun et al., 2009; Vescovi et al., 1999). To induce differentiation, cells were grown 
in medium containing 1% fetal bovine serum (FBS) or 1µM retinoic acid (RA) (Galli et 
al., 2004; Ying et al., 2011). Primary GBM neurospheres 551 (JHH551) and 612 
(JHH612) were derived directly from clinical GBM specimens obtained at Johns Hopkins  
Hospital using the same methods and culture conditions as described by Galli et al. 
(2004). Primary neurospheres were used at less than 10 passages. All human materials 
were obtained and used in compliance with the Johns Hopkins Institutional Review 
Boards.  
 
Lentiviral Cell Transfection 
The sequences for CD151 shRNA lentiviral vectors (TRCN0000300360, 
TRCN0000300331; Sigma-Aldrich; V3THS_308057; Thermo Scientific, Hudson, NH, 
www.thermoscientific.com) are listed below.  N-terminal 3xFLAG-tagged KLF9 and 
CD151 were constructed with high-fidelity polymerase chain reaction (PCR; Roche, 
Basel, Switzerland, www.roche-appliedscience.com) and cloned into pTRIPZ vector 
(Thermo Scientific, Hudson, NH, www.thermoscientific.com) and/or pLEX vector 
(Thermo Scientific) using AgeI and MluI restriction sites. ITGA6 was also cloned into 
pLEX vector with AgeI and Mlul. Lentiviral packaging followed second generation 
lentivirus packaging protocol using psPAX2 and pMD2.G vectors (Addgene, Cambridge, 
MA, www.addgene.org). Glioma cells were infected with lentivirus at a multiplicity of 
infection of 5 and selected with puromycin (1 µg/ml) for stable cell lines. Transdux 
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(System Biosciences, Mountain View, CA, http://www.systembio.com) was used for 
improving lentivirus infection efficiency.  
CD151 shRNA sequences 
CD151 shRNA 1 CCGGGCTGGAGATCATCGCTGGTATCTCG
AGATACCAGCGATGATCTCCAGCTTTTTG 






Neurosphere formation assays 
Viable cells (2 x 103/well or 2 × 104/well) were cultured in 48-well or 6-well 
plates, respectively. After 7-14 days, neurospheres were fixed in medium with 1% 
agarose, stained with 1% Wright stain solution and counted by computer-assisted 
morphometry (MCID software, Cambridge, UK, www.mcid.co.uk) by measuring the 
number of neurospheres (>50 μm or >100 μm in diameter, as indicated) in three random 
fields per well. 
Cell Adhesion Assay 
Six well plates were coated with laminin at 37°C overnight and washed twice 
with phosphate buffered saline (PBS). Dissociated viable cells (1.0 ml) were plated at a 
density of 5 x 105/ml and incubated for 24 hours. Neurosphere cells expressing a Dox-
inducible 3F-KLF9 transgene: Cells were then transfected ± lentivirus containing the 
ITGA6 transgene. After 24 hours, cells were treated ± Dox for 96 hours. Primary cells 
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were co-transfected with KLF9 and ITGA6 lentivirus. Neurosphere cells expressing a 
Dox-inducible 3F-CD151 transgene were treated ± Dox for 24 hours. The cells were then 
dissociated and plated (5 x 105/mL) on laminin coated six-well plates for 2-6 hours. Cells 
were stained with crystal violet (5 µg/µl) (Sigma-Aldrich) for 10 minutes. Crystal violet 
was dissolved with 2% SDS and quantified spectrophotometrically at 550 nm using a 
Spectra MAX 340pc (Molecular Devices, Sunnyvale, CA) plate reader.  The results are 
shown as relative adhesion measured after subtracting the background absorbance from 
all values. 
 
Cell Migration Assay 
Cell migration assays were performed using 24mm transwell chambers with 
8.0µm pore-size polycarbonate membranes (Corning Inc, Corning, NY, 
http://www.corning.com). The upper chambers were coated with laminin at 37°C 
overnight followed by washing with PBS 3 times. Dissociated neurosphere cells 
expressing a Dox-inducible 3F-KLF9 transgene were co-transfected with KLF9 and 
ITGA6 lentivirus. After 24 hours, cells were treated ± Dox for 48 hours in growth factor-
free neurosphere culture medium. Primary cells were transfected with KLF9 lentivirus. 
GBM neurosphere lines were infected by CD151 shRNA lentivirus or incubated with 
anti-CD151 (integrin α3 binding site) antibody TS151r (Millipore) for 24 hours. 
Neurosphere cells expressing a Dox-inducible 3F-CD151 were treated ± Dox for 24 
hours. The cells were then suspended in 1.5ml (1 x 106cells/well) of growth factor-free 
neurosphere culture medium and added to the upper chamber of the transwell. Minimum 
Essential Medium Eagle medium (2.6 ml) supplemented with 10% FBS was added to the 
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lower chamber. After 24 hours of incubation at 37°C, the transwell upper chamber 
surfaces were gently scrubbed with a cotton swab to remove non-invasive cells. Cells that 
had migrated through the filter were fixed with 4% paraformaldehyde and stained with 
Hoechst 33342 nucleic acid stain (Invitrogen, Carlsbad, CA, www.invitrogen.com). 
Migration was quantified by counting cells from eight random fields and averaged.   
Migration of glioma cells was also quantified using a directional migration assay 
using a multi-well nanopatterned device, consisting of parallel nano-ridges/grooves of 
400 nm in groove width, 400 nm in ridge width, and 500 nm in depth, constructed of 
transparent poly(urethane acrylate) (PUA), and fabricated using UV-assisted capillary 
lithography as previously described (D. H. Kim, Han, et al., 2009; D. H. Kim, Seo, et al., 
2009). Prior to plating cells, nanogrooved substrata were coated with poly-D-ornithine 
(10 ug/ml concentration) for 15 minutes and laminin (3ug/cm2) overnight. These 
topographically patterned cell substrata, cause cells to align with and move along the 
direction of the nanogrooves. Cell migration was quantified using timelapse microscopy 
and a motorized inverted microscope (Olympus IX81) equipped with a Cascade 512B II 
CCD camera and temperature and gas controlling environmental chamber. Phase-contrast 
and epi-fluorescent cell images were automatically recorded under 4*1.6X objective 
using the Slidebook 4.1 (Intelligent Imaging Innovations, Denver, CO) for 10 hours at 10 
minute intervals. 
A custom-made MATLAB script was used to calculate cell speed using timelapse 
microscopy data as described previously (Abbadi et al., 2014; Garzon-Muvdi et al., 2012; 
Kondapalli et al., 2015; Q. Li et al., 2014).  Average speeds of individual cells were 
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calculated from the total distance moved throughout the entire cell trajectory and the total 
time the cell was tracked. 
Western Blot 
Total cellular proteins were extracted with radioimmunoprecipitation assay buffer 
(Sigma-Aldrich) containing protease and phosphatase inhibitors (Calbiochem, Billerica, 
Massachusetts, www.calbiochem.com). The Subcellular Protein Fractionation Kit was 
used for membrane protein extraction (Thermo Scientific). SDS-PAGE was performed 
with 50 μg total cellular proteins using 4% to 12% gradient Tris-glycine gels (LI-COR 
Biosciences, Lincoln, NE, www.licor.com). Western blot analysis was performed using 
Quantitative Western Blot System, with secondary antibodies labeled by IRDye infrared 
dyes (LI-COR Biosciences). The primary antibodies were: anti-CD151, anti-Olig2, anti-
FLAG (Santa Cruz), anti-Sox2, anti-pAkt, anti-tAkt, anti-integrin α3, anti-integrin α6, 
anti-integrin β1 (Cell Signaling), anti-pan Cadherin (Abcam, Cambridge, MA, 
www.abcam.com), anti-β-actin (Sigma-Aldrich), anti-FLAG-HRP (Sigma-Aldrich), anti-
BMI1 (Cell Signaling), anti-Nestin (Santa Cruz) and anti-CD133 (Cell Signaling).  
 
Immunoprecipitation 
A total of 1 x 107 GBM1A 3F-CD151 cells were treated ± Dox for 48 hours. Cells 
were lysed in the immunoprecipitation buffer containing 1% Brij-O1, 20mM Tris HCl pH 
8, 137mM NaCl, 2mM EDTA and protease and phosphatase inhibitors (Calbiochem) for 
1 hour at 4°C on a rotating shaker. Mouse anti-FLAG M2 antibody (Sigma-Aldrich) or 
Protein A/G magnetic beads (Thermo Scientific) crosslinked with mouse IgG (served as 
the control) were added to the above cell lysate and incubated overnight at 4°C on a 
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rotating shaker. 3F-CD151 bound complexes were eluted using 3x FLAG peptide 
(Sigma-Aldrich). Immunoprecipitates were immunoblotted with primary antibodies or 
analyzed by tandem mass spectrometry (LC/MS/MS) by the Johns Hopkins University 
Mass Spectrometry and Proteomics Facility. 
 
Immunofluorescence 
Neurosphere cells were collected by cytospin onto glass slides and fixed with 4% 
paraformaldehyde. Cells were permeabilized by Triton X-100 and immunostained with 
anti-GFAP (Sigma-Aldrich), anti-β-actin (Sigma-Aldrich), anti-CD151 (Santa Cruz 
Biotechnology, Dallas, TX, www.scbt.com), anti-integrin α3 ( Cell Signaling), anti-
integrin α6 (Cell Signaling), and/or anti-integrin β1 (Cell Signaling) antibodies and 
Hoechst 33342 nucleic acid stain (Invitrogen) following the protocol from Cell Signaling. 
Secondary antibodies were conjugated with Alexa488 or Cyanine Cy3. 
Immunofluorescent images were captured and analyzed using Axiovision software 
(Zeiss, Thornwood, NY, www.zeiss.com). 
 
Flow Cytometric Assay 
Flow cytometric analysis was done on unfixed cells were stained with 
CD133/2(AC133)-PE (Miltenyi Biotec, Auburn, CA, www.miltenyibiotec.com), PE-
CD151 (BD Biosciences, San Jose, CA, www.bdbiosciences.com)  or ITGA6-FITC 
(CD49f; BD Pharmingen, Franklin Lakes, NJ, www.bdbiosciences.com) antibody 
following manufacturer’s protocol using a FACSCalibur (Becton Dickinson, San Jose, 
CA, http://www.bd.com) with with CELLQuest Version 3.3 software (Becton 
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Dickinson). The cells were blocked with Fc receptor blocking reagent and incubated at 
4°C with CD133/2 (AC133)-PE for 10 minutes or with PE-CD151 or ITGA6-FITC for 
30 minutes. The cells were then washed and resuspended in PBS containing 0.5% BSA 
and 2 mM EDTA. Mouse IgG labeled with PE or FITC (Miltenyi Biotec) was used as 
control. 
 
Tumor implantation and animal treatments 
All animal protocols were approved by the Johns Hopkins School of Medicine 
Animal Care and Use Committee.  
For subcutaneous (s.c.) xenografts, female athymic nude mice were injected s.c. 
in the flank with 5 × 106 viable neurosphere cells in 0.1 ml DMEM. When tumors 
reached about 50 mm3, mice were randomly divided into groups for treatment. Dox was 
administered in animal feed. Tumor sizes were determined daily by measuring two 
dimensions (length [a] and width [b]) and volumes (V) were calculated using the 
formula V = ab2/2 (Lal, Xia, Abounader, & Laterra, 2005). 
For intracranial (i.c.) xenografts, SCID immunodeficient mice received 5,000 
viable neurosphere cells (determined by trypan blue staining) in 2 μL Dulbecco’s 
Modified Eagle Medium by stereotactic injection to the right caudate/putamen (AP = 0 
mm, ML = −2.5 mm, DV = −3.0 mm). Mice were perfused with 4% paraformaldehyde at 
the indicated times and the brains were removed for histological analysis. Tumor sizes 
were quantified by measuring maximum tumor volume on hematoxylin and eosin–stained 
brain coronal sections using computer-assisted morphometry (MCID software).  
Histology and immunohistochemistry 
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Laminin immunohistochemistry was performed using anti-laminin antibody to 
detect orthotopic xenograft vascularization (Ljubimova et al., 2004). The tumor blood 
vessels were quantified as total vessel area relative to tumor cross-sectional area, as 
previously described (Abounader et al., 2002). Activated caspase-3 
immunohistochemistry was conducted using anti-cleaved caspase-3 (Cell Signaling 
Technology, Beverly, MA). Apoptotic indices were determined by computer assisted 
quantification of the number of positively stained cells per microscopic field as 
previously described (Abounader et al., 2002; Lal et al., 2005). 
Quantitative real-time PCR 
Total RNA was extracted using Rneasy Mini Kit (Qiagen, Venlo, Limburg, 
www.qiagen.com). After reverse transcription using MuLV reverse transcriptase 
(Applied Biosystems, Calsbad, CA, www.appliedbiosystems.com) and Oligo(dT) primer, 
quantitative real-time PCR (qRT-PCR) was performed using SYBR Green PCR Mix 
(Applied Biosystems) and IQ5 detection system (Bio-Rad, Hercules, CA, www.bio-
rad.com). Primer sequences are listed below. Relative gene was normalized to 18S rRNA. 
Primer sequences for quantitative real-time PCR. Fold enrichment was 
calculated using the following formula: 2^–(Ct Flag IP-Ct Mouse IgG IP). The 
percentage of input was calculated using 100 x 2^(adjusted input-Ct Flag IP), where the 








RAP2A   
TCTACAGCCTCGTCAACCAGCA 
TCTGCCTTCGCTGGACGATACT 
CAMK2G   
GACACGGTAACTCCTGAAGCCA 
TCCACAGTCTCCTGACGATGCA 
CDC42   
TGACAGATTACGACCGCTGAGTT 
GGAGTCTTTGGACAGTGGTGAG 
MAPK3   
TGGCAAGCACTACCTGGATCAG 
GCAGAGACTGTAGGTAGTTTCGG 
PAK4   
GATGATTCGGGACAACCTGCCA 
AGGAATGGGTGCTTCAGCAGCT 
PIK3C2B   
CCTCCTGAAACGAGCTGTGTCT 
CACAGTAAGGCTGCCAGCAGAT 
PIK3R2   
ATGGCACCTTCCTAGTCCGAGA 
CTCTGAGAAGCCATAGTGCCCA 
RND2   
GAGCTGTCCAAGCAGAGGCTTA 
GAGCACTCAACATAGGACACAGC 
SOS1   
GGAGATCAACCCTTGAGTGCAG 
TGCTCTACCCAGTGCCGACATA 
SOS2   
GGCATATCAGCAAACCAGGACAG 
CACTCCCTACAAGTTCAGACGG 




GNAQ   
GATCAGAGCCATGGACACACTC 
GCAGACACCTTCTCCACATCAAC 
ITGA6   
CGAAACCAAGGTTCTGAGCCCA 
CTTGGATCTCCACTGAGGCAGT 
ITGA9   
TCAGGTCACAGAGAAGCTGCAG 
CACATGCTCACTGAGGCTGTAG 
ARPC1B   
CTCCTGTGACTTCAAGTGTCGG 
GGCTGAGAAACAGACGCCATGT 
CAPN5   
AGTGTGAGGGAGACAAAGTCCG 
CATCCTTCAGCACTCGGTGGTT 
MAP3K11   
CTGGATGGCTCCTGAGGTTATC 
CACAGCAAGGCAGTCAATGCCA 
MYLK   
GAGGTGCTTCAGAATGAGGACG 
GCATCAGTGACACCTGGCAACT 
GIT1   
CCGAGAGTTTGCCACCTTGATC 
ACGCTGTCGTAGTCGTGTTGGT 
ADAM17   
AACAGCGACTGCACGTTGAAGG 
CTGTGCAGTAGGACACGCCTTT 
NOTCH1   
GGTGAACTGCTCTGAGGAGATC 
GGATTGCAGTCGTCCACGTTGA 




NUMBL   
CTACGGCTGAATGAGCTGCCAT 
CAGAGCGTTGATGCTGTCACTG 
DTX1   
AGAATCCCGAGGATGTGGTTCG 
TCGTAGCCTGATGCTGTGACCA 
APH1B   
AGGTGAGACAGCACCCTCTATG 
GAGGAGAATCTCCATGAATGCCC 
HES1   
GGAAATGACAGTGAAGCACCTCC 
GAAGCGGGTCACCTCGTTCATG 
HEY2   
TGAGAAGACTTGTGCCAACTGCT 
CCCTGTTGCCTGAAGCATCTTC 















RNA Isolation and RNA Sequencing 
Total RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA, 
www.qiagen.com) following the manufacturer’s protocol. 4 µg total RNA was subjected 
to library preparation using Illumina TrueSeq RNA Sample Preparation Kit v2 (Illumina, 
San Diego, CA, www.illumina.com) following manufacturer’s protocol. Indexed adapters 
were used in order to pool 4 cDNA libraries into one sequencing reaction. Libraries were 
quantified and quality control was assessed using an Agilent Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, http://www.genomics.agilent.com/) to confirm that 
cDNA fragment sizes were between 200bp and 500bp in length. Sequencing was 
performed using Illumina HiSeq 2500 platform (Illumina). 
 
RNA-Seq Analysis 
The raw reads were aligned to reference human genome build hg18 using TopHat 
(Trapnell, Pachter, & Salzberg, 2009) with default parameters. See Figure 3.2C for the 
percentage of reads aligned. For each gene, the number of reads aligned to its exons were 
counted and summarized into gene level counts by R bioconductor package 
GenomicFeatures (M. Carlson et al.) based on UCSC refFlat table for hg18. 
Normalization between samples was carried out by R package edgeR (Robinson, 
McCarthy, & Smyth, 2010; Robinson & Oshlack, 2010), which controls sequencing 
depth and RNA composition effects, i.e. high expression of some genes in a sample may 
contribute a substantial proportion of total reads and thus undersample reads from other 
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genes. The consistency of RNA-Seq data for the two biological replicates was examined 
by scatter plot for log2 fold changes between the two cell lines for all genes and by 
heatmap for expression patterns for differentially expressed genes. 
 
Reproducibility Plots for RNA-Seq Data 
RPKM, namely reads per kilobase per million mapped reads, for each 
differentially expressed gene was calculated by R bioconductor package GenomicRanges 
(M. Carlson et al.).The heatmap (Figure 3.2D) was generated according to the count table 
with scaling across the samples for each gene. The log2 fold change, 
log2((IPRMKM+1)/(ControlRPKM+1)), for each gene in each cell line was calculated. 
The log2 fold change for KLF9-GBM1b is plotted against that of KLF9-GBM1a (Figure 
3.2E).  
 
KLF9 Target Gene Detection 
Differential gene expression detection was carried out by R bioconductor package 
edgeR (Robinson et al., 2010) with tagwise dispersion at FDR 5%. A matched study 
design was used since the four samples came from two cell lines. The list of differentially 
expressed transcripts was further filtered if the absolute values of log2 fold changes for 
differentially expressed transcripts comparing the case vs control exceeded 0.8. KLF9 
target genes were defined as differentially expressed transcripts with ≥1 KLF9-binding 
peak in the -20 kb to +10 kb window surrounding the transcription start sites (TSSs). 
 
Chromatin Immunoprecipitation (ChIP) and ChIP Sequencing  
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A total of 5 x 106 KLF9-GBM1a and KLF9-GBM1b cells were treated with Dox 
for 48 hours and subjected to ChIP using MAGnify ChIP system (Invitrogen, Carlsbad, 
CA, www.invitrogen.com) following manufacturer’s protocol. KLF9 bound DNA was 
immunoprecipitated using mouse anti-FLAG M2 antibody (Sigma-Aldrich) and 
Dynabeads Magnetic Beads (Life Technologies). Mouse IgG served as the control.  
ChIP-enriched DNA was purified using the minElute Reaction Cleanup kit (Qiagen, 
Valencia, CA) and used in semi-quantitative PCR and qPCR reactions with primer pairs 
and sequencing. 10ng ChIP-enriched DNA or input DNA was subjected to library 
preparation using ChIP-Seq DNA Sample Prep Kit (Illumina) following manufacturer’s 
protocol. Quality control using an Agilent Bioanalyzer (Agilent Technologies) was 
performed to assure that ChIP-enriched and input DNA library had similar DNA size 
distribution patterns of between 150-250 bp in length. Sequencing was performed using 
Illumina HiSeq 2500 platform (Illumina). 
Primer sequences for Chromatin Immunoprecipitation quantitative real-time PCR. 
Primer Name Sequence (5'-3') 
RHOV KLF9 Binding Site  
CTCTGACTGAATGGGTCCAG 
TGCCTGCCTTTCCTCCTCC 
CAMK2G KLF9 Binding Site  
GAGAGCGAGGGAGGGAGG 
GCGAGGGCGGCTCCGGG 
SOS1 KLF9 Binding Site  
GAGGACGTGTGGAGGGACG 
CCTCAGGGCAGCCAGATTC 




ITGA6 BTE Site B  
ACGTCGTGGCTTCCGGGCAGGTA 
GGAGACTCGCAGGCGTTTTATCAAG 
MYLK KLF9 Binding Site   
CTCAAACCACCCGCTCCAG 
GTGCAGGATAAGTGCGAGG 
NOTCH1 KLF9 Binding Site   
GAGAGGCTGGGCTCGGGACG 
GAGGCACTAGTGAGGCTC 
NUMBL KLF9 Binding Site  
GATGGTGCGGGATGCACG 
CGGGGTCTTCAGGCCAAG 
ITGA6 KLF9 Binding Site/BTE Site 
A   
CCAGAGCCGGCGGGTAAGGTG 
CGAGGCTGCCGCGCTGCTGCTA 
ITGA6 No BTE Site 1   
GCTTTATGAGTATCTTGGCACAGTA 
GGGGCGGTTGGAGGGAAAATGG 
ITGA6 No BTE Site 2   
GACTGGCTGATCCTCCTTTAGA 
ATTTTTGTCATTGCCCCTCACTTT 
NOTCH1 BTE Site   
CGGGTCCCTCCTCCCCGGAG 
CCTCCCGCGGCCGAGGCACT 
NOTCH1 No KLF9 Binding Site   
CAGCTGGGCCCTCGTGTTTC 
CCTGGCCTGGCGCTCTTCCT 
RAP2A KLF9 Binding Site   
GATCTGGGCGTGGAGGCGCG 
GGCAACTGAGGGAGCAGC 




PSEN2 KLF9 Binding Site   
CCTCTGGCCACGGTCCCTTC 
GAAGTGGGGACGCAGTGAG 
HEY2 KLF9 Binding Site   
CTGGCCCAGCCAATCGCGAG 
CTAGCGGCTCTTTCCCAC 
ITGA9 KLF9 Binding Site  
GAAGTGCGCGCAGGGCTCAC 
GGGCGCTGAAGGCGAGCACA 
ARPC1B KLF9 Binding Site   
CGACGTCTGCGCGGGTACC 
GACTCTGGGCAGTCGACGCG 
GIT1 KLF9 Binding Site   
GCTTCTGCAGGAAGCGGCGC 
CCCACGCGGAAAGTGAAGGG 
Random Genomic Region 1   
GTCTGTACTCCCAGCTACTC 
GACAGAGCAAGACTCCATC 
Random Genomic Region 2   
GTGTCAAAGCTCGGAACTG 
GGTGCCAGGTGATCCCAAC 
Random Genomic Region 3   
CTGCACTTGGCCAATATTTC 
CTTTGCTGACCCATTTTATTC 
Random Genomic Region 4   
CTAAGGCCACACAGCTAG 
CTATTAGAACCCCGAGATC 
Random Genomic Region 5   
CGTGAGCCAATTTCCCAAC 
GTTTCTCCCTACTTTGTC 




Random Genomic Region 7   
CTTAGGAATAAATTTAAC 
CATTGGGATTTTAATAG 
Random Genomic Region 8   
GTGTATGTATAAAGAATG 
CTTGTTAAACTTTTATAG 
Random Genomic Region 9   
GACTGGTTCATTCACTGCTC 
CACTTCCCTACCCGAAAC 





    The 50 bp long raw KLF9 ChIP-Seq reads were aligned to the reference human 
genome build hg18 using Bowtie (Langmead, Trapnell, Pop, & Salzberg, 2009) allowing 
at most two mismatches in the first 28 bp “seed” bases. See Figure 3.3E for the 
percentage of reads aligned. KLF9 binding sites were called using CisGenome (Ji et al., 
2008) with default settings by comparing the two IP samples against the two control 
samples. At false discovery rate (FDR)   (Benjamini, Drai, Elmer, Kafkafi, & Golani, 
2001)of 1%,  3,1261 binding peaks were identified.  
 
Reproducibility Plots for ChIP-Seq Data 
    The number of reads aligned to the peak regions by each of the four ChIP samples was 
counted by R bioconductor package GenomicRanges (M. Carlson et al.) and then 
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normalized for the library size for each sample. In the resulting count table, each column 
represents a peak region and each row corresponds to a sample. For each peak region, its 
normalized counts in a given sample was further subtracted by its mean normalized 
counts across samples and then divided by its standard deviation, which gave the scaled 
binding intensity. The heatmap (Figure 3.3F) shows the scaled binding intensities for 
each peak in each sample.  As shown in the heatmap, the two control samples from both 
cell lines are clustered together and the two IP samples are clustered together by 
hierarchical clustering with complete linkage.  After correcting for library size, the log2 
IP intensity, log2(IPreads+1), for each peak in both cell lines was also calculated. The 
log2 IP intensity for cell line KLF9-GBM1b is plotted against that of cell line KLF9-
GBM1a (Figure 3.3G, correlation= 0.8750). Both the heatmap and the scatter plot 
demonstrate that the IP intensities at KLF9 binding peaks were consistent for both 
biological replicates. 
 
De novo Motif Discovery 
    The 150 bp long sequences centered at the peak summits for the top ranked 500 peaks 
were extracted and fed as the input for de novo motif discovery algorithm of CisGenome. 
Ten motifs of varying length with mean motif length being 12 were searched 
simultaneously. To obtain the truly KLF9 enriched motifs, the occurrence rate of motif in 
the 150 bp long sequences centered at the peak summits for all peaks was compared with 
its occurrence rate in  control genomic regions. The control regions were randomly 
chosen to match the GC content and distributional properties of ChIP-Seq peak regions 
(Ji, Vokes, & Wong, 2006). Of all the motifs, only one motif has an enrichment score 
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exceeding 5 (with value= 5.446253) and it was selected as the binding motif for KLF9. 
See Figure 3.3J. 
 
ChIP-Seq Peak List Annotation and RNA-Seq Target Gene List Generation 
    Figure 3.3I displays the peak distribution within the neighborhood of gene 
transcription start sites (TSS). Each identified peak was annotated by the closest gene 
satisfying the condition that the peak locates within the (-20 kb to 10 kb) neighborhood of 
the gene’s TSS according to UCSC refLocus table for hg18. Each peak was classified as 
up regulated region, down regulated region, non-differentially expressed region and not-
annotated region according to the differential expression status of its corresponding gene. 
On the other hand, for the gene list, each gene was annotated as whether it has KLF9 
binding peaks within its (-20 kb to 10 kb) neighborhood of TSS and whether its binding 
peaks contain motif sequences or not. For all the 24,524 transcripts and 18,275 genes in 
the refLocus table, 16,030 transcripts and 11,995 genes have KLF9 binding peaks within 
their (-20 kb to 10 kb) neighborhoods of TSS. 
 
Pathway Analyses 
    Canonical pathway analysis was performed using Ingenuity Pathway Analysis (IPA, 
http://www.ingenuity.com). The significance of association between KLF9 targets and a 
canonical pathway was measured using the ratio between the number of KLF9 targets in 
the pathway and the total number of molecules in the pathway database. A Fisher’s exact 





Other Statistical Methods 
    Cell response data (excluding ChIP-Seq and RNA-Seq as described above) were 
analyzed using Prizm software (GraphPad, La Jolla, CA, www.graphpad.com). Statistical 
differences were evaluated by ANOVA followed by Student’s t test and the Tukey 
multiple comparison tests as appropriate. All data are represented as mean value ± SEM. 





KLF9 Regulates a Transcriptional Network in GBM 
3.1 KLF9 expression and Glioblastoma Cell Stemness 
We previously found that induction of endogenous KLF9 expression associates 
with and is required for GBM neurosphere cell responses to forced differentiation and 
that enforced KLF9 expression inhibits GBM cell stemness and suppress the activity of 
Notch signaling, a known stemness-supporting pathway (Ying et al., 2011).  In order to 
identify whole genome KLF9 targets linked to neurosphere cell stemness inhibition, we 
first established appropriate GBM neurosphere cell models and KLF9 induction 
conditions.  The magnitude change in endogenous KLF9 expression was quantified in 
GBM-derived neurospheres following exposure to two inducers of GSC differentiation, 
retinoic acid (RA) and serum following EGF/FGF withdrawal (B. Campos et al., 2010; 
Galli et al., 2004; Pollard et al., 2009; Ying et al., 2011). These differentiating conditions 
induced a 10-12 fold increase in KLF9 expression concurrent with increased cell 
expression of the neuronal marker β-tubulin III (TUJ1) and the astroglial marker glial 
fibrillary acidic protein (GFAP) (Figure 3.1 A-B).  Two human GBM neurosphere lines 
were engineered to express a Dox-inducible 3xFLAG-tagged KLF9 transgene 
(designated KLF9-GBM1a and KLF9-GBM1b) (Figure 3.1C), and Dox treatment for 48 
hours induced KLF9 mRNA expression ~28-fold, comparable to the magnitude of 
endogenous KLF9 induction in response to RA and serum treatment (Figure 3.1D). KLF9 
protein levels plateaued by 2 days of Dox treatment and quickly diminished 12-24 hours 
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after Dox withdrawal (Figure 3.1E).  We examined the effects of 3xFLAG-KLF9 
induction on the expression of molecular markers and drivers of GBM cell stemness. The 
percentage of CD133-positive cells in KLF9-GBM1a and KLF9-GBM1b neurospheres 
was reduced from 59.3% to 36.9% and from 64.0% to 41.6%, respectively, following 
KLF9 induction (Figure 3.1F). BMI1, Nestin, Olig2 and Sox2 expression levels also 




Figure 3.1. KLF9 is induced by forced differentiation by either RA or serum in 
GBM-derived neurospheres and reduces stem cell marker expression. (A) GBM1b 
cells were treated with either RA (1µM) or 1% FBS for 48hours. Expression of KLF9 
was analyzed using quantitative real-time polymerase chain reaction (qRT-PCR). KLF9 
expression is induced by FBS and RA. (B) GBM1b cells were cultured in neurosphere 
medium with 1% fetal bovine serum (FBS). FBS induces GFAP and TUJ1 expression as 
shown by immunofluorescence staining of control neurospheres and adherent serum-
treated cells. (C) Schematic representation of the 3FLAG-tagged KLF9 construct. 
3FLAG-tagged KLF9 ectopic expression vector was constructed using pTRIPZ vector 
(Open Biosystems) as described in Methods. TRE: tet-inducible promoter. UBC: human 
ubiquitin C promoter driving rtTA3 expression of rtTA3 and IRES-puro. rtTA3: reverse 
tet-transactivator. IRES: internal ribosome entry site. Puro’: mammalian selectable 
marker. (D) Stable GBM1b cells established from cells infected with lentivirus 
containing Dox-inducible 3FLAG-tagged KLF9 (KLF9-GBM1b) were treated ± Dox for 
48 hours. Expression of KLF9 was analyzed using qRT-PCR to show KLF9 expression is 
induced by Dox. (E) KLF9-GBM1b cells were treated ± Dox for 6 days and then 
passaged into Dox free medium for 2 days. Whole cell lysate was collected from cells on 
the days indicated and analyzed by immunoblot staining with anti-FLAG antibody 
demonstrating that KLF9 expression returns to baseline expression quickly following 
Dox withdrawal. (F) Stable GBM1a cells engineered to express a Dox-inducible N-
terminal FLAG-tagged KLF9 (KLF9-GBM1a) and KLF9-GBM1b cells were treated ± 
Dox for 6 days and analyzed by flow cytometry using CD133 antibodies and isotope IgG 
control. A representative histogram and quantification of CD133+ cells are shown. (G) 
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GBM neurospheres were treated ± Dox for 6 days. Whole cell lysate was collected from 
the cells and analyzed using immunoblot staining. KLF9 reduces the protein level of 






3.2 KLF9 Gene Binding and Gene Expression Signatures 
A genome-wide analysis of KLF9 targets was performed by combining gene 
expression profiling and transcription factor binding site mapping in GBM neurospheres 
following KLF9 induction (strategy outlined in Figure 3.2A). KLF9-GBM1a and KLF9-
GBM1b cells were treated ± Dox for 48 hours after which RNA was isolated, reverse 
transcribed to create cDNA libraries (Figure 3.2B) that were then subjected to deep 
sequencing.  Over 16 million cDNA reads were generated for each of four samples 
representing two biological replicates (KLF9-GBM1a and KLF9-GBM1b) with or 
without KLF9 induction (Figure 3.2C). Consistency between the two RNA-Seq datasets 
was confirmed by heat map and scatter plot analyses (Figure 3.2D; Figure 3.2E). Of all 
the 24,524 RefSeq transcripts (18,275 genes), 1,550 transcripts (1,161 genes, 6.4%) were 
upregulated (log2 (Fold Change)) ≥ 0.8, Ying et al., 2014) and 2,843 transcripts (2,092 
genes, 11.4%) were downregulated (log2 (Fold Change)) ≤ -0.8, Ying et al., 2014) in 
response to KLF9 induction (Figure 3.2F).   
Genome-wide KLF9 binding sites were identified using ChIP-Seq in GBM 
neurospheres. Cellular chromatin bound by 3xFLAG-KLF9 was specifically precipitated 
using anti-FLAG antibody and the specific ChIP-enriched DNAs (150-250 bps in length) 
were further processed to produce libraries for ChIP-Seq (Figure 3.3A & B). The quality 
of the ChIP-Seq library was assessed using qPCR directed at Notch1 promoter elements 
previously found by us to bind KLF9 and mediate  Notch1 suppression (Figure 3.3C-D) 
(Ying et al., 2011). Over 150 million reads were generated from ChIP-enriched DNA and 
input controls derived from two biological replicates (Figure 3.3E). Using CisGenome, 
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31,261 KLF9 binding peaks were called at a false discovery rate (FDR) of 1% (Ji et al., 
2008) (Ying et al., 2014).  The ChIP intensities within KLF9 binding peaks were 
consistent for both biological replicates as shown by heat map and scatter plot analyses 
(Figure 3.3F; Figure 3.3G). The majority of KLF9 binding sites were found to be located 
in intergenic regions (54.0%) and introns (35.9%), and binding sites localized less 
frequently to 5’- untranslated regions (7.3%), exons (10.9%) and 3’ -untranslated regions 
(1.2%) (Figure 3.3H).  KLF9-binding sites were found to be highly enriched around 
transcription start sites (TSSs) (Figure 3.3I). The top 500 KLF9 ChIP-Seq peaks as 
ranked by their FDR were used to perform de novo motif discovery analysis.  The 
consensus sequence 5’ G/A G/T GGG C/T G G/T GGCN 3’ was identified as the most 
enriched KLF9 binding motif (Figure 3.3J). This motif closely resembles the motifs of 
two Sp1/KLF family members, KLF4 (5’-NGGG T/C G G/T GG-3’) and Sp1 (5’-




Figure 3.2. Identification of KLF9 gene expression and binding signatures by ChIP-
Seq and RNA-Seq analyses. (A) Flow chart of analyses used to identify KLF9 gene 
targets. KLF9-GBM1a and KLF9-GBM1b cells were treated ± Dox to induce KLF9 
expression for 48 hours. cDNA and ChIP DNA libraries obtained from the treated cells 
were analyzed by RNA-Seq and ChIP-Seq to reveal KLF9 binding peaks and 
differentially expressed transcripts following KLF9 induction, respectively. KLF9 
targets, differentially expressed transcripts that are also bound by KLF9 following KLF9 
induction, were determined by combing ChIP-Seq and RNA-Seq data. (B) KLF9-GBM1a 
and KLF9-GBM1b cells were treated ±Dox for 48 hours to induce KLF9 expression. 
RNA was collected, reverse transcribed and fragmented to create a cDNA library for 
RNA-Seq analysis. Fragment length was between 150bps and 500bps. (C) Total number 
of RNA-seq reads and the percentage of reads aligned to the hg18 using TopHat are 
shown for control samples from KLF9-GBM1a and KLF9-GBM1b cells (indicate as 
control A and control B, respectively) and samples treated with Dox for 48hours  from 
KLF9-GBM1a and KLF9-GBM1b cells (indicated as KLF9 A and KLF9 B, 
respectively). (D) Heatmap of expression pattern for differentially expressed genes from 
RNA-Seq data. Reads per kilobase per million mapped reads (RPKM) for each 
differentially expressed gene was calculated by R bioconductor package GenomicRanges. 
In the count table, each column represents a peak region and each row corresponds to a 
sample. The heatmap was generated according to the count table with scaling across the 
samples for each gene. (E) RNA-Seq reproducibility scatter plot. The log2 (Fold Change) 
for each gene in each cell line was calculated. The log2 (Fold Change) for KLF9-GBM1b 
genes is plotted against that of KLF9-GBM1a genes. (F) Volcano plot of all genes 
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analyzed for differential expression. The log2 (Fold Change) between control and Dox-
treated cells is plotted along the x axis. The false discovery rate (FDR) for each gene is 
plotted on the y axis (−log2 scale). Red indicates genes that have an FDR less than or 
equal to 0.05 and a log2 (fold change) greater than 0.8.  The dashed horizontal line 








Figure 3.3. Identification of KLF9 gene expression and binding signatures by ChIP-
Seq and RNA-Seq analyses. (A) KLF9-GBM1a cells were treated with Dox for 48 
hours. anti-FLAG antibody but not nonimmune IgG specifically precipitated FLAG-
tagged KLF9 from fragmented DNA-protein complexes. (B) KLF9-GBM1a cells were 
treated with ±Dox for 48 hours. DNA fragments precipitated had a length was between 
150bps and 250bps. (C) Schematic of the human Notch1 promoter (-10,000 to +1 bp 
relative to the ATG site; BTE1: GGGGCGGGGC; BTE2: GGGGCGGAGC; Notch1 
transcription start site: -262 bp). Segment A and B indicate the locations of amplified 
sequences used for analysis of chromatin immunoprecipitation as described in (D). (D) 
DNA fragments were precipitated with anti-FLAG antibody and analyzed with 
polymerase chain reaction (PCR) primer pairs designed to amplify BTE-free and BTE-
containing Notch promoter sequences. anti-FLAG antibody coprecipitated BTE-
containing (segment B) but not BTE-free (segments A) promoter regions. (E) Total 
number of ChIP-seq reads and the percentage of reads aligned to the hg18 using Bowtie 
are shown for control samples from KLF9-GBM1a and KLF9-GBM1b cells (indicate as 
control A and control B, respectively) and samples treated with Dox for 48hours  from 
KLF9-GBM1a and KLF9-GBM1b cells (indicated as KLF9 A and KLF9 B, 
respectively). (F) Heatmap of IP intensities for identified peaks in KLF9 ChIP-Seq data. 
The number of reads aligned to the peak regions by each of the four ChIP samples was 
counted by R bioconductor package GenomicRanges and then normalized for the library 
size for each sample. In the count table, each column represents a peak region and each 
row corresponds to a sample. The heatmap was generated according to the count table 
with scaling across the samples for a given peak.  The two control samples from both cell 
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lines are clustered together and the two IP samples are clustered together by hierarchical 
clustering with complete linkage. (G) ChIP-Seq reproducibility scatter plot. After 
correcting for library size, the log2 IP intensity for each peak in both cell lines was also 
calculated. The log2 IP intensity for cell line KLF9-GBM1b is plotted against that of cell 
line KLF9-GBM1a. (H) The genomic distribution of KLF9-binding sites relative to 
human genes shows that the majority of KLF9 binding peaks are located in intergenic 
regions and introns. (I) The peak frequency near known transcription start sites (TSS)s 
reveals that KLF9-binding sites are enriched around TSSs. (J) The KLF9-binding motif 
was discovered using a CisGenome de novo motif discovery algorithm. The enrichment 
score of the KLF9 binding motif, determined by dividing its occurrence frequency in 
randomly sampled genomic matched control sequences, is 5.45. (K) When compared to 
all know motifs in JASPAR (Bryne et al., 2008), KLF4 and Sp1 motifs are the most 
similar ones to our discovered KLF9 motif. The enrichment scores for the KLF4 and Sp1 
motifs, determined by dividing its occurrence frequency in randomly sampled genomic 
matched control sequences, are 3.34 and 2.59 respectively. Abbreviations: BTE, basic 
transcription element; GBM, glioblastoma; IP, Immunoprecipitation KLF, Krüppel-like 
family of transcription factor, Sp, specificity protein, GBM, glioblastoma; IP, 
Immunoprecipitation; KLF, Krüppel-like family of transcription factor; TSS, 








3.3 Analysis of KLF9-regulated Gene Targets 
KLF9 ChIP-Seq and RNA-Seq datasets were combined to establish gene targets 
directly regulated by KLF9 (i.e. genes differentially expressed in response to KLF9 
induction and having one or more KLF9-binding peaks within -20kb to +10kb of their 
TSSs). The expression of KLF9-bound and unbound genes is summarized in Figure 3.4A. 
Among the 2,843 transcripts downregulated by KLF9, 2,465 (86.7%) fulfilled these 
criteria. This number was significantly higher than random (i.e. the number of KLF9 
bound transcripts found among 2,843 transcripts selected randomly 1,000 times from the 
genome; see Figure 3.4B, top panel, p-value =0). In contrast, among the 1,550 
upregulated transcripts, only 972 (62.7%) were directly bound by KLF9, a number 
indistinguishable from that found in 1,000 randomly selected sets of 1,550 transcripts 
(Figure 3.4B, bottom panel). These results indicate that the predominant role of KLF9 is 
to serve as a transcriptional repressor. Therefore, we focused the functional analyses 
described below exclusively on the 2,465 KLF9 downregulated transcripts (Ying et al., 
2014). 
Gene function annotation and Ingenuity Pathway Enrichment Analysis (IPA) 
were performed using KLF9 downregulated transcripts, as described above (Thomas & 
Bonchev, 2010; Xia & Wishart, 2010). The top pathways enriched with KLF9 
downregulated targets included those active in cancer regulation (e.g. molecular 
mechanisms of cancer, CXCR4 signaling, integrin signaling and notch signaling), stem 
cell pluripotency signaling (mouse embryonic stem cell pluripotency) and signaling in 
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neurons (axonal guidance signaling, CREB signaling in neurons and semaphorin 
signaling in neurons) (Figure 3.4C).  
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Figure 3.4. Analyses of KLF9-regulated gene targets. (A) The percentage of all genes 
that show differential expression following KLF9 induction and had one or more KLF9 
binding peaks within +20 to-10 kb of their TSS. (B) The frequencies of KLF9 binding to 
2,092 randomly selected down-regulated genes (top panel) or to 1,161 randomly selected 
up-regulated genes (bottom panel) were determined 1,000 times to generate null 
distributions (red bars). The dashed lines correspond to the number of KLF9 down-
regulated or up-regulated genes identified by ChIP-Seq and RNA-Seq. Only the number 
of KLF9 down-regulated genes differs significantly from the null distribution. (C) 
Pathways enriched in KLF9 down-regulated gene targets determined by Ingenuity 
Pathway Analysis. Pathways are ranked by –log(pvalue) calculated by Fisher’s exact test. 
The ratio was calculated by dividing the number of KLF9 targets genes in the pathway 
with the total number of genes in the pathway (ratio threshold, 0.05).GNRH, 
gonadotropin-releasing hormone; NFAT, nuclear factor of activated T cells; CREB, 








A subset of the KLF9 downregulated genes selected from pathways highly ranked 
by IPA (e.g. molecular mechanisms of cancer, CXCR4 signaling, Integrin signaling, 
Notch signaling) was further validated by qPCR in KLF9-GBM1b neurospheres and low-
passage primary GBM neurospheres (GBM 551) (Figure 3.5A).  The validated genes 
included Notch pathway members NOTCH1, PSEN2 and NUMBL; CXCR4—a gene 
encoding a chemokine receptor that contributes to cytoskeletal organization and mediates 
metastasis in various cancers and CAMK2G—a gene encoding a serine/threonine protein 
kinase that has been associated with the proliferation, resistance and survival of cancer 
cells. Integrin signaling, which modulates multiple cellular processes including cell 
adhesion and migration, tumor cell invasion and cell stemness (Lathia et al., 2010; 
Takada, Ye, & Simon, 2007), was one of the top ranked and validated pathways enriched 
with KLF9 suppressed gene targets. ITGA6, encoding integrin α6 receptor subunit, was 
downregulated by up to 89% following KLF9 induction.  Other downstream components 
of the integrin signaling pathway, such as ARPC1B, CAPN5, GIT1 and MYLK, were also 
validated to be downregulated following KLF9 induction by up to 88%, 74%, 72% and 
71%, respectively (Figure 3.5A). The presence of KLF9 binding peaks near the TSS of 
12 KLF9 repressed genes was validated further by ChIP-PCR (Figure 3.5B & C). 
Quantitative ChIP-PCR was also employed to compare the enrichment of ChIP-Seq 
identified KLF9-binding peaks of 7 targets to the enrichment of genomic regions located 
either 10 or 20kb upstream. (Figure 3.5D). The ChIP-Seq identified peaks showed higher 




Figure 3.5. Validation of KLF9 Gene Expression Regulation and Gene Binding. (A) 
3xFLAG-KLF9 expression was induced in KLF9-GBM1b cells and low-passage primary 
GBM derived neurospheres (551) by Dox and lentivirus, respectively, for 48hours. 
Expression inhibition of a subset of the KLF9 target genes identified to be downregulated 
by ChIP-Seq and RNA-Seq analyses was validated by quantitative RT-PCR. (B-D) 
KLF9-GBM1b cells were treated + Dox and subjected to ChIP-PCR using anti-FLAG 
antibody and primer pairs designed to amplify promoter regions of KLF9 target genes 
containing at least one KLF9 binding motif (See Materials and Methods for details). (B) 
Representative tracks show the locations of KLF9 ChIP-Seq peaks proximal to the 
transcription start site (TSS)s of KLF9 gene targets identified by ChIP-seq and RNA-seq 
analyses.  Red boxes indicate peaks validated by ChIP qPCR. (C) Quantitative ChIP-PCR 
analysis showing enrichment of the KLF9-binding motifs described in (B). (D 
Quantitative ChIP-PCR showing selective enrichment of KLF9-binding motifs in 
downregulated KLF9 target genes. Enrichment of ChIP-Seq identified binding peaks 
located in 7 downregulated KLF9 targets and DNA regions -10kb or -20kb upstream of 
these peaks is shown. Results show that KLF9-binding motifs are selectively enriched by 
anti-FLAG ChIP in Dox-treated KLF9-GBM1b cells. Data represents mean ± SEM; *, p 









KLF9 negatively regulates GSCs, in part, by suppressing 
integrin α6 gene expression and downstream functions   
Integrin α6 is the most upstream component of the integrin signaling pathway that 
was identified to be regulated by KLF9 (Figure 4.1). Also, among the integrin pathway 
genes, ITGA6 was found to be one of the most downregulated by KLF9 and its promoter 
had one of the most highly enriched KLF9-bound chromatin peaks. A detailed analysis of 
the integrin signaling pathway revealed that KLF9 inhibits GSC self-renewal and 
differentiates GBM stem cells, in part, by suppressing integrin-α6 gene expression and 





Figure 4.1. Integrin signaling pathway enriched with KLF9 downregulated targets. 
Ingenuity pathway analysis (IPA) representation of the integrin signaling pathway. 






4.1 KLF9 directly binds ITGA6 promoter 
One KLF9 binding motif was identified in the human ITGA6 promoter at -396 
bps relative to the TSS (referred to as basic transcription element, BTE, site) (Figure 
4.2A). This site was also found to be conserved in the mouse ITGA6 promoter (data not 
shown). KLF9 binding to this ITGA6 promoter region was confirmed in KLF9-GBM1b 
neurospheres by ChIP-PCR. FLAG-KLF9 co-precipitated with ITGA6 promoter regions 
containing the BTE site (segment A and B) but not with control regions lacking a BTE 
site (segment C and D) (Figure 4.2A and B). BTE-containing segments A and B were 
enriched compared with control segments C and D (Fig. 3.2B, 16.4 and 67.8 fold 
enrichment for segments A and B vs. 4.3 and 0.9 fold enrichment for segments C and D, 
respectively). 
4.2 KLF9 down-regulates integrin 6 expression 
    The effects of KLF9 induction on the level of integrin α6 mRNA and protein were 
quantified in two GBM neurosphere lines and two low passage primary GBM 
neurosphere isolates.  KLF9 induction inhibited ITGA6 mRNA levels in all cell cultures 
(Figure 4.3A) and also inhibited integrin α6 protein expression (Figure 4.3B).  We further 
examined the dynamics of ITGA6 expression in response to ectopic KLF9 expression 
controlled by Dox. ITGA6 expression levels changed inversely with KLF9 levels; ITGA6 
expression decreased along with KLF9 induction and rapidly returned to baseline levels 
after Dox withdrawal (Figure 4.3C). The effect of KLF9 expression on the number of 
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integrin α6-positive cells within neurospheres mirrored its effects on bulk-culture integrin 
α6 levels. KLF9 induction reduced integrin α6-positive neurosphere cells within 














Figure 4.2. KLF9 directly binds to the ITGA6 promoter. (A) Schematic of the human 
ITGA6 promoter with a KLF9 binding peak identified by ChIP-Seq (-25,000 to +3,000bp 
relative to TSS). Primers were designed for segments A-D. (B & C) Dox-treated KLF9-
GBM1b cells were subjected to ChIP using FLAG antibody and mouse IgG. Selective 
enrichment in qPCR (B) and conventional PCR (C) was detected for BTE-containing 




Figure 4.3. KLF9 regulates integrin α6 expression. (A) ITGA6 expression was 
measured by qPCR in GBM neurosphere lines and primary GBM neurospheres after 
KLF9 induction for 48h. (B) KLF9 was induced by Dox for 96h in GBM1a and GBM1b 
cells. Membrane protein extraction was subjected to immunoblotting against integrin α6. 
(C) KLF9-GBM1b cells were treated with Dox for 6 days, passaged to Dox-free medium 
for 6 days, and then passage again to Dox-containing medium for 6 days. Cells were 
collected on the days indicated and subjected to qPCR for ITGA6 and KLF9. ITGA6 
expression levels changed inversely with Dox-induced KLF9 expression. (D) KLF9-
GBM1b cells were treated ± Dox for 96h and subjected to flow cytometry using anti-
Integrin-α6-FITC antibody or isotype IgG control. Representative dot plots and the 
percentages of Integrin α6-positive cells are shown. Data represents mean ± SEM; *: 




4.3 ITGA6 repression by KLF9 regulates GBM neurosphere 
cell adhesion and migration and stem cell marker expression 
    We asked if KLF9 modulates GBM cell behavior and stemness by regulating integrin 
α6 expression. To this end, we examined how KLF9 induction modulates GSC adhesion 
and migration on laminin, an integrin α6 ligand and essential component of the 
perivascular niche that supports neoplastic stem-like cells (Lathia et al., 2012; Q. Shen et 
al., 2008). KLF9 was induced in GBM neurospheres for 4 days and cells were then 
transferred to laminin-coated tissue culture substrata. Control cells rapidly attached and 
spread within 2-6 hours. KLF9 induction inhibited cell spreading (Figure 4.4A, left 
panel) and decreased cell adhesion by 25-71% (Figure 4.4A, right panel). We asked if 
enforced integrin α6 expression could rescue the cell adhesion defects induced by KLF9. 
Lentivirus vectors were used to express KLF9, integrin α6, or both in GBM neurospheres 
for 48-96 hours prior to assessing cell adhesion and spreading on laminin.  Enforced 
integrin α6 expression partially rescued the effect on cell spreading (Figure 4.4A, left 
panel) and abrogated KLF9’s ability to inhibit cell adhesion by approximately 71%, 48%, 
64% in the three GBM neurosphere cultures (Figure 4.4A, right panel). Migration 
through laminin-coated transwell membranes was reduced in response to KLF9 induction 
by 62-86% (Figure 4.4B). Enforced expression of integrin α6 also rescued cells from 
KLF9-induced cell migration inhibition (Figure 4.4B). 
    Integrin α6 is highly expressed in various stem cells (Lathia et al., 2010; Shinohara, 
Avarbock, & Brinster, 1999) and cell surface expression was found to be enriched in 
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GSCs and to maintain GSC self-renewal and tumorigenicity (Lathia et al., 2010). We 
hypothesized that KLF9 regulates glioma cell stemness in part by regulating integrin α6 
expression. KLF9 downregulated the expression of multiple inducers and markers of the 
stem-like phenotype GBM neurospheres (Figure 6C).  Enforced integrin α6 expression 
reversed KLF9-induced suppression of CD133, Nestin, Sox2, BMI1 and Olig2 
expression (Figure 4.4C). These results support the conclusion that KLF9 regulates 
molecular markers and drivers of GSC stemness, in part, by repressing ITGA6. 
4.4 Integrin 6 expression rescues KLF9-induced growth 
inhibition of glioma xenografts 
    We found previously that KLF9 induction reduces the growth of intracranial tumor 
xenografts established from GBM neurospheres and extends the survival of mice bearing 
xenograft tumors (Ying et al., 2011).  We hypothesized that KLF9 reduces xenograft 
tumor growth in part by repressing integrin α6 expression. We investigated the effects of 
expressing KLF9, integrin α6, or both on the growth of intracranial (i.c.) xenografts 
established from GBM-derived neurospheres. KLF9, integrin α6, or both were expressed 
in GBM neurosphere cells by lentivirus infection (Figure 4.5A) and cells were implanted 
to the brains of immunocompromised mice 48h after virus infection. Mice (n=4 for each 
group) were sacrificed 60 days post transplantation and coronal histological brain 
sections were examined for tumor size. Enforced KLF9 expression significantly inhibited 
tumor xenograft growth compared to control xenografts (tumor volume ± SEM (mm3): 
86 
 
9.0 ± 2.9 vs 34.4 ± 6.1, p<0.01). Integrin α6 expression rescued tumor growth inhibition 





Figure 4.4. ITGA6 repression by KLF9 regulates GBM neurosphere cell adhesion, 
migration and stem cell marker expression. KLF9, ITGA6, or both were expressed in 
GBM neurosphere lines and primary GBM neurospheres. (A) KLF9-GBM1b cells were 
passaged onto laminin-coated culture substrata for 2-6h. Cell adhesion was evaluated by 
phase contrast microscopy (Left Panel) and quantitatively by spectrophotometric analysis 
of crystal violet-stained cells (Right Panel). KLF9 expression inhibited cell adhesion. Co-
expressing Integrin α6 partially rescued cell adhesion inhibition by KLF9. (B) Cells were 
passaged to laminin-coated transwell membranes. Cell migration was evaluated 24 hours 
later by analyzing DAPI-stained cells. KLF9 expression inhibited transmembrane 
migration, which was rescued by Integrin α6. (C) Transfected KLF9-GBM cells were 
maintained in neurosphere growth medium for 96 hrs. Whole cell lysates were subjected 
to immunoblotting to assess the expression of FLAG-KLF9, Integrin α6, and the stem 
cell markers CD133, Nestin, SOX2, BMI1, and Olig2. Relative expression of each 
protein (normalized to Actin) is shown below each band. KLF9 inhibited the expression 
of stem cell markers and this response was partially rescued by enforced Integrin α6 
expression.  
Bar: 50 µm. Data represents mean ± SEM; *: p<0.05, **: p<0.01, ***: p<0.001, One-












Figure 4.5. Integrin α6 expression rescues KLF9-Induced growth inhibition of 
glioma xenografts. GBM1b neurospheres were infected with lentivirus to express 
FLAG-KLF9, Integrin α6 or both. (A) Immunoflourescence of neurosphere cells shows 
the expression of ectopic FLAG-KLF9 and Integrin α6 (bar: 50 µm). (B) Equal numbers 
of viable cells were transplanted into the brains of SCID mice (n=4). H&E-stained 
coronal brain sections obtained from post implantation day 60 animals are shown (bar = 1 
mm). (C) Quantification of tumor xenograft volumes shows that KLF9 induction 
inhibited xenograft growth and that integrin α6 expression rescued KLF9-induced anti-
tumor response.  
Data represents mean ± SEM; *: p<0.01, **: p<0.001, One-way ANOVA followed by 





CD151 regulates glioblastoma stem cell stemness and 
tumorigenity, in part, through interactions with laminin-
binding integrins 
5.1 KLF9 dynamically regulates CD151 expression 
 
The effects of KLF9 induction on the level of CD151 mRNA and protein were 
quantified in two GBM neurosphere lines.  KLF9 induction inhibited CD151 mRNA 
levels in all cell cultures (Figure 5.1A).  We further examined the dynamics of CD151 
expression in response to ectopic KLF9 expression controlled by Dox. CD151 expression 
levels changed inversely with KLF9 levels; CD151 expression decreased along with 
KLF9 induction and rapidly returned to baseline levels after Dox withdrawal (Figure 
5.1B).  
5.2 CD151 is highly expressed in glioma subtypes and GSCs 
 
To examine the expression profile of CD151 in normal brain and glioma tissues, 
samples from the Repository for Molecular Brain Neoplasia Data (REMBRANDT) 
database (National Cancer Institute, https://caintegrator.nci.nih.gov/rembrandt/), which 
includes 28 non-tumor tissue and 443 glioma tissue samples, were analyzed. Analysis of 
CD151 mRNA expression revealed that CD151 expression is 4.9-, 2.1- and 2.1- fold 
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higher in GBM, oligodendroglioma, and astrocytoma, compared to non-tumor brain 
samples, and 2.3- and 2.4- fold higher in GBM samples compared to oligodendroglioma, 
and astrocytoma samples, respectively (Figure 5.2A).   
To investigate potential correlations between CD151 expression and clinical 
outcome, we analyzed the prognostic significance of CD151 in the REMBRANDT 
samples using Kaplan-Meir survival curve analysis with a log-rank comparison. As 
shown in Figure 5.2B, survival for patients expressing upregulated CD151 was 
significantly shorter compared to those with intermediate expression in all glioma and 
specific glioma subtypes (p < 0.001, p = 0.008, p = 0.027 and p = 0.012 in all glioma, 
GBM, oligodendroglioma and astrocytoma samples, respectively, log-rank test). 
We examined CD151 expression in GBM-derived neurosphere lines (GBM1A 
and GBM1B) and low passage GBM-derived primary neurospheres (612) enriched in 
GSCs. Immunostaining detected CD151 expression in permeabilized neurosphere cells 
(Figure 5.2C). CD151 was found to be expressed in membrane but not cytoplasmic 
fractions of multiple GSC lines using immunoblot analysis of membrane and cytoplasmic 
protein (Figure 5.2D). CD151 expression was further examined by qPCR analysis of 
CD133+ neurosphere cell subpopulations, which are widely considered to represent 
GBM-propagating SCs (Singh et al., 2004). CD151 expression was elevated in CD133+ 
cells relative to CD133- cells (Figure 5.2E).  
To further study the association of CD151 with cell stemness and stemness-
driving transcription factors, CD151 expression was analyzed using qPCR in GBM-
derived neurospheres engineered to overexpress Oct4 and Sox2 (GBM1A Oct4/Sox2). 
Co-expressing transgenic Oct4 and Sox2, previously shown by us to induce tumor-
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propagating GSCs (Lopez-Bertoni et al., 2014), increased CD151 expression 3- fold 
(Figure 5.2F). These results show that CD151 is upregulated in the most aggressive 
gliomas and CD151 upregulation is associated with poor prognosis independent of 
glioma grade. CD151 expression is also highly upregulated in glioma-propagating stem 




Figure 5.1 KLF9 regulates CD151 expression. (A) CD151 expression was measured by 
qPCR in GBM neurosphere lines after KLF9 induction for 48h. (B) KLF9-GBM1b cells 
were treated with Dox for 6 days, passaged to Dox-free medium for 6 days, and then 
passage again to Dox-containing medium for 6 days. Cells were collected on the days 
indicated and subjected to qPCR for CD151. CD151 expression levels changed inversely 





Figure 5.2. CD151 expression in glioma and glioma stem cells (GSCs). (A) CD151 
mean gene expression intensity from REMBRANDT database (*, #: p<0.0001 compared 
with non-neoplastic brain or GBM, respectively). CD151 expression is significantly up-
regulated in glioblastoma multiforme (GBM) samples when compared with non-
neoplastic brain, oligodendroglioma or astrocytoma samples. (B) Kaplan-Meier Survival 
Plots for glioma patients based on differential gene expression of CD151 (from 
REMBRANT database). The probability of survival is significantly lower in samples 
with high CD151 gene expression compared to samples with intermediate expression in 
all glioma, GBM, astrocytoma and oligodendroglioma samples (P < 0.001; P < 0.01; P = 
0.01; P < 0.05). Inclusion of patients with low CD151 expression was not possible due to 
insufficient sample size. (C) Fluorescent photomicrography of GBM1B neurospheres 
permeabilized with triton X-100 and immunostained using anti-CD151 antibody (green 
fluorescence). Blue fluorescence indicates DAPI nuclear stain (bar = 10 μm). (D) 
Membrane and cytoplasmic protein fractions isolated from GBM neurosphere lines 
(GBM1A, GBM1B) and primary GBM neurosphere (612) were subjected to immunoblot 
analysis with anti-CD151 antibody. CD151 localizes to membrane, but not the cytoplasm 
of examined glioma stem cells. (E) GBM1A neurosphere cells expressing undetectable 
and high levels of CD133 (CD133-, CD133+, respectively) were separated by flow 
cytometry. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis shows 
that CD151 mRNA expression is significantly higher in CD133+ cells (*, P < 0.01 
compared to CD133- cells). (F) CD151 expression was analyzed by qPCR in GBM1A 
and GBM1A cells overexpressing stemness-associated transcription factors Oct4 and 
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Sox2 (GBM1A Oct4/Sox2). CD151 mRNA expression is higher in GBM1A Oct4/Sox2 








5.3 CD151 expression regulates GSC self-renewal and CD151 
knockdown impairs GSC proliferation  
To determine if CD151 is essential to GSC stemness, GBM-derived neurospheres 
were transduced with lentiviral CD151 shRNAs (CD151 shRNA 1 and CD151 shRNA 
2). CD151 protein and mRNA expression were significantly inhibited by each CD151 
shRNA (Figure 5.3A and B) that decreased the number of CD151+ cells up to 99% 
(Figure 5.3C). We also engineered three independent neurosphere lines to express a Dox-
inducible N-terminal 3xFLAG-tagged CD151 transgene (3F-CD151; designated as 
GBM1A 3F-CD151, GBM1B 3F-CD151 and 612 3F-CD151). Dox treatment for 48 
hours induced expression of CD151 mRNA and membrane-associated CD151 protein 
(Figure 5.3D and E). 
The effects of CD151 silencing on GSC self-renewal and cell proliferation were 
examined. Self-renewal as neurospheres, was markedly inhibited by  CD151 knockdown 
from 61% to 96% in multiple neurosphere lines and primary isolates, including 
neurospheres derived from mesenchymal (M1123) and proneural (P146) glioblastoma 
subtypes (Figure 5.4A and B). Conversely, forced CD151 expression significantly 
increased neurosphere formation (Figure 5.4C). CD151 silencing impaired cell 
proliferation, somewhat more modestly, from 34% to 63% (Figure 5.4D). However, 






Figure 5.3. CD151 knockdown and Dox-inducible CD151 forced expression in 
glioma neurospheres. (A-C) GBM neurospheres (GBM1A and GBM1B) were 
transduced with lentivirus coding for control shRNA, CD151 shRNA 1 or CD151 shRNA 
2. CD151 expression was quantified by (A) immunoblot analysis of membrane protein 
collected 72 hours later using anti-CD151 antibody and (B) quantitative real-time 
polymerase chain reaction (qPCR) analysis of mRNA. (C) Neurosphere cells were 
analyzed by flow cytometry 6 days after transduction with lenti-CD151 shRNA using 
CD151 antibodies and isotype IgG control. CD151 knockdown significantly reduced the 
number of CD151+ cells. Representative histograms and the percentage of CD151+ cells 
are shown. (D & E) GBM-derived neurosphere cells expressing a Dox-inducible 3FLAG-
tagged CD151 (GBM1A 3F-CD151 and GBM1B 3F-CD151) were treated ± Dox. CD151 
expression was analyzed by (D) immunoblot of cell membrane fractions using antibodies 
against CD151 and Flag and by (E) quantitative real time polymerase chain reaction 48 












Figure 5.4. Effects of CD151 on neurosphere formation and neurosphere self-
renewal and viability. (A & B) GBM neurosphere lines (GBM1A, GBM1B, M1123, 
P146) and primary GBM neurospheres (612) were transduced with lentivirus coding for 
control shRNA, CD151 shRNA 1 or CD151 shRNA 2. (A) Equal numbers of viable cells 
were cultured for 14 days post transduction to form neurospheres.  (Bar = 100 μm) 
Representative microscopic images of GBM1B neurospheres with control or CD151 
shRNA are shown. (B) Neurospheres ( >100 μm diameter) were counted. CD151 
silencing inhibited neurosphere formation in all neurosphere isolates examined. (C) 
GBM1A 3F-CD151 and GBM1B 3F-CD151 neurospheres were treated ± Dox. Viable 
cells were cultured for 7 days ± Dox to form neurospheres. Neurospheres (>100 μm 
diameter) were quantified. CD151 overexpression increased neurosphere formation. (D 
& E) GBM1A, GBM1B, M1123 and 612 neurospheres were infected with lentivirus 
coding for control shRNA, CD151 shRNA 1 or CD151 shRNA 2. Cells were stained with 
Trypan blue. Viable (unlabeled) cells and labeled cells were counted on the days 
indicated post transduction. CD151 knockdown (D) inhibited cell growth, but (E) did not 







5.4 CD151 expression regulates expression of stemness associated 
markers and regulators 
We investigated the effect of CD151 silencing on the expression of markers and 
regulators of GBM cell stemness. CD151 knockdown in neurospheres reduced the 
number of CD133+ cells by 32%-52% (Figure 5.5A and B). GSCs are regulated by 
several stemness-associated transcription factors, including Olig2 and Sox2 (Gangemi et 
al., 2009; Y. Li et al., 2011; Lopez-Bertoni et al., 2014). CD151 silencing decreased 
expression of Sox2 and Olig2 on a protein level and Sox2, Olig2 and BMI1 on an mRNA 
level (Figure 5.5C and D).  Conversely, forced CD151 expression increased expression of 
stemness associated factors Oct4, Sox2, Olig2 and BMI1 (Figure 5.5E and F). Taken 




Figure 5.5. CD151 regulates GBM cell stemness. (A-D) GBM1A and GBM1B 
neurospheres were transduced with lentivirus coding for control shRNA, CD151 shRNA 
1 or CD151 shRNA 2. (A & B) GBM1A and GBM1B cells were analyzed by flow 
cytometry 6 days post transduction using anti- CD133 and isotope IgG control. (A) A 
representative histogram and the percentages of CD133+ cells are shown. (B) CD151 
silencing decreases the number of CD133+ cells. (C) Total cell lysates were extracted 
and analyzed by immunoblot for Sox2, Olig2 and β-Actin. CD151 inhibition decreases 
expression of Sox2 and Olig2. (D) CD151 silencing inhibits Sox2, Olig2 and BMI1 
mRNA expression, as shown by quantitative real time polymerase chain reaction (qPCR) 
analysis. (E & F) GBM1A 3F-CD151 and GBM1B 3F-CD151 neurospheres were treated 
± Dox. Whole cell extracts were analyzed by immunoblot for Olig2 and Sox2. (E) 
CD151 overexpression promotes expression of Olig2 in both cells and Sox2 in GBM1B 
3F-CD151 GSCs. (F) Analysis of Oct4, Sox2, Olig2 and BMI1 expression by qPCR 








5.5 Targeting CD151 inhibits GSC migration and adhesion on laminin  
GBM-derived neurosphere cells transduced with control lentivirus or with 
lentiviral vectors engineered to express either CD151 shRNA were seeded on laminin-
coated transwell membranes to evaluate migration capacity. CD151 silencing reduced 
migration 47%- 87% (Fig 5.6A and B).In contrast, forced CD151 expression enhanced 
cell migration on laminin-coated transwells by 42% to 109% in GBM1A 3F-CD151, 
GBM1B 3F-CD151 and 612 3F-CD151 cells (Figure 5.6C). 
The glioma microenvironment constitutes a physically and chemically diverse 
terrain that influences cell migration. For example, glioma cells preferentially migrate 
along structured pathways such as myelinated neuronal tracts and blood vessels (Bellail, 
Hunter, Brat, Tan, & Van Meir, 2004). To further study the effect of CD151 on GSC 
migration and how this effect is influenced by an ECM mimicked environment, 612 cells 
transfected with control or CD151 shRNA lentivirus were seeded on a laminin-coated 
substrate consisting of nanoscale grooves. Migration along the nanoscale ridges enables a 
more precise assessment of migration parameters such as cell speed and distance 
travelled over several hours. CD151 silencing significantly reduced average cell 
migration speed by 41% to 57% (Figure 5.6D and E). Control shRNA transfected cells 
also traveled at higher maximum speeds than CD151 shRNA transfected cells (Figure 
5.6F). CD151 knockdown also reduced the average distance migrated over 10 hours (Fig 
5.6G and H).  
Cell adhesion events impact cell migration capacity. To determine if CD151 
modulates neurosphere cell adhesion, GBM-derived neurosphere cells transduced with 
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control lentivirus or lentivirus coding for CD151 shRNA were seeded on a laminin 
coated substrata. CD151 silencing resulted in a delayed rate of adhesion and cell 
spreading (Figure 5.6I and J). Forced CD151 expression had no effect on cell adhesion 2 
hours after seeding on a laminin-coated surface, but significantly increased adhesion after 
6 hours (Figure 5.6K). Collectively, the data indicates that CD151 regulates neurosphere 




Figure 5.6. CD151 regulates GBM neurosphere cell adhesion and migration. (A-C) 
GBM neurospheres (GBM1A, GBM1B, P146, M1123, 612) were transduced with 
lentivirus coding for control shRNA, CD151 shRNA 1 or CD151 shRNA 2 cDNA or 
GBM1A 3F-CD151, GBM1B 3F-CD151 and 612 3F-CD151 neurospheres were treated ± 
Dox for 24 hours. Cells were plated on laminin-coated transwell membranes and 
migration was evaluated 8 hours later by counting DAPI-stained cells. (A) Representative 
microscopic fields of GBM1B neurosphere cells transduced with control or CD151 
shRNA lentivirus are shown (Bar = 50 μm). Cells per field were counted. (B) CD151 
silencing inhibited migration on laminin while (C) CD151 overexpression promoted 
migration on laminin. (D-J) GBM neurospheres (GBM1A, GBM1B, M1123, 612) were 
transduced with lentivirus coding for control shRNA, CD151 shRNA 1 or CD151 shRNA 
2 cDNA., Cells were plated on a laminin-coated multi-well nanopatterned device used to 
track brain tumor-propagating cell migration. Cell migration was recorded for 10 hours 
and individual cells were tracked using a custom MATLAB program. (D) The average 
cell speed travelled per 10 minute interval and (E) the overall average speed were 
calculated. (F) A histogram of average speed for individual cells is shown.  Control cells 
migrate faster than CD151 shRNA transduced cells. (G) Average distance migrated was 
calculated. CD151 knockdown reduced cell distances travelled. (H) Representative 
trajectories of control shRNA and CD151 shRNA cells are shown (Bar = 100 μm). The 
start location (red dots) and final locations at 10 hours (blue dots) of individual cells are 
shown. The green line indicates the path traveled by individual cells. (I & J) Cells were 
plated on a laminin-coated tissue culture substrata for 2 and 6 hours. Cell adhesion and 
morphology were evaluated by phase-contrast microscopy (Bar = 100 μm) and 
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quantitatively by spectrophotometric analysis of crystal violet-stained cells. CD151 
silencing (I) inhibited cell spreading and (J) delayed cell adhesion. (K) GBM1A 3F-
CD151, GBM1B 3F-CD151 and 612 3F-CD151 neurospheres were treated ± Dox for 24 
hours.  Adhesion was evaluated by spectrophotometric analysis of crystal violet-stained 
cells 2 and 6 hours after cells were plated on a laminin-coated surface. CD151 expression 
promoted adhesion 6 hours after seeding. Data, mean ± SEM; *, P < 0.05 when compared 







5.6 CD151 silencing impairs growth of GSC-derived tumor xenografts 
and pathological angiogenesis 
A most crucial characteristic of GSCs is the ability to propagate tumors in vivo. 
Hence, we examined the effects of CD151 silencing on the growth of subcutaneous (s.c) 
and intracranial (i.c.) xenografts established from GBM-derived neurospheres. 
Subcutaneous xenografts were established in mice with M1123 neurosphere cells 
engineered to express a Dox-inducible CD151 shRNA (M1123 CD151 shRNA). A 
randomly selected subset of mice was transitioned to Dox feed when tumors reached 
50mm3. Tumors were measured from post implantation day (PID) 8 through PID 15 to 
monitor the effects of CD151 silencing. Average tumor size increased from 74 mm3 to 
1,853 mm3 in control mice and from 85 mm3 to 540 mm3 in Dox treated mice. By PID 15, 
CD151 shRNA had inhibited tumor growth by 71% (Figure 5.7A).  CD151 knockdown 
in vivo was confirmed by immunoblot of whole tumor protein extracts using CD151 
antibody (Figure 5.7B).   
To examine the effect of CD151 silencing on i.c. tumor formation, GBM1A cells 
were infected with lentiviral control or CD151 shRNA. Viable cells were implanted 24 
hours later into the brains of severe combined immunodeficiency (SCID) mice. Mice 
were sacrificed 52 days later and coronal brain sections were examined for tumor size. 
Tumor formation was significantly reduced in mice implanted with CD151 shRNA 
treated cells (19.1 ± 3.9 mm3 max tumor volume) compared to control shRNA tumors 
(54.3 ± 5.0 mm3 max tumor volume) (Figure 5.7C and D). 
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We also examined tumor cell apoptosis by immunohistochemistry (IHC) staining for the 
apoptosis marker, cleaved caspase-3. We found that silencing CD151 in pre-established 
M1123 s.c. xenografts increased the percentage of cells expressing active cleaved 
caspase-3 by 3.7- fold (Figure 5.7E and F). To investigate the role of CD151 on GBM 
tumor xenograft vascularization, vessels were visualized in s.c. tumor sections by IHC 
staining with antibody against laminin. Vascular index decreased by 43% in response to 
CD151 shRNA (Figure 5.7G and H). Taken together, the data supports that targeting 
CD151 inhibits the growth of neurosphere-derived GBM xenografts by targeting cell 
survival and angiogenic mechanisms.  
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Figure 5.7. CD151 knockdown inhibits the growth of neurosphere-derived tumor 
xenografts. (A and B) Mice were implanted subcutaneously with Dox-inducible M1123 
CD151 shRNA cells. Mice were started on Dox in rodent diet when tumors reached 
50mm3. Tumor sizes were measured as described in “Materials and Methods”. (A) 
CD151 knockdown inhibited xenograft growth. (B) Protein extractions from 
subcutaneous xenografts obtained at day 15 were analyzed by immunoblot for CD151, 
confirming Dox-induced knockdown of CD151. (C and D) GBM1A cells were 
transduced with lentivirus coding for control shRNA or CD151 shRNA cDNA. After 24 
hours, 5,000 cells were transplanted into the brains of severe combined 
immunodeficiency (SCID) mice.  (C) Hematoxylin and eosin-stained coronal brain 
sections (20 μm) obtained from animals on PID 52 are shown (Bar = 1 mm). (D) 
Quantification of xenograft tumor volume shows that silencing CD151 repressed 
xenograft growth (H; P < 0.001 when compared with control shRNA). (E-H) 
Subcutaneous xenografts from mice implanted with Dox-inducible M1123 CD151 
shRNA cells were examined for cell apoptosis by (E) immunohistochemistry (IHC) using 
anti-cleaved caspase-3 antibody (Bar = 10 μm). Labeled cells were quantified by 
computer-assisted image analysis. (F) CD151 silencing increased cell apoptosis (p<0.001 
compared to controls). (G) S.c. xenografts were examined by anti-laminin IHC (Bar = 
10μm). (H) Computer-assisted quantification shows that CD151 knockdown decreased 






5.7 CD151 modulates integrin-dependent signaling and cell behavior in 
GSCs 
CD151 complexes with laminin-binding integrins and influences integrin driven 
biological processes in several cell types (Sterk et al., 2002; Winterwood, Varzavand, 
Meland, Ashman, & Stipp, 2006). Integrins are also highly expressed in stem cells, 
including GSCs, and thought to contribute to stemness by anchoring stem cells to certain 
micoenvironmental niches (S. Chen, Lewallen, & Xie, 2013; Lathia et al., 2010). 
Immunofluorescent staining showed that CD151 colocalizes with integrins α3, α6 and β1 
in the plasma membrane of GBM neurosphere cells (Figure 5.8A). To further investigate 
CD151’s association with integrins, GBM1A 3F-CD151 neurosphere cells were treated ± 
Dox for 48 hours to induce CD151 expression. Immunoprecipitation using anti-FLAG 
revealed associations between CD151 and integrins α3, α6 and β1 (Figure 5.8B).  
We then investigated the effect of CD151 expression on activation of the integrin 
signaling pathway in GBM neurosphere cells. We found that CD151 knockdown reduced 
phosphorylation of Akt, a downstream effector of integrin signaling that promotes 
various biological processes including survival and cell motility (Cox, Natarajan, 
Stettner, & Gladson, 2006), while forced CD151 expression enhanced Akt 
phosphorylation (Figure 5.8C and D). 
To determine if interactions between CD151 and integrins are required for CD151 
modulated GSC behavior, we treated cells with the anti-CD151 antibody TS151r 
previously shown to block the interaction between CD151 and integrins α3 and α6 
(Kazarov et al., 2002; Serru et al., 1999; Sterk et al., 2002; Yauch, Kazarov, Desai, Lee, 
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& Hemler, 2000). Incubation with the TS151r mimicked CD151 expression knockdown 
by multiple criteria. TS151r reduced neurosphere formation by 77%-95% (Figure 5.8E), 
reduced cell migration on laminin by 70%-75% (Figure 5.8F), and inhibited Akt 
phosphorylation (Figure 5.8G). Taken together, the results strongly support a mechanism 
by which CD151-laminin interactions support GSC self-renewal and migration in part by 
altering integrin function and downstream signaling. 
To verify CD151’s association with integrins α3, α6 and β1 and to determine what 
other proteins CD151 may interact with in GSCs to influence GSC behavior, GBM1A 
3F-CD151 neurosphere cells were treated ± Dox for 48 hours to induce CD151 
expression. Proteins immunoprecipitated with anti-Flag were analyzed by tandem mass 
spectrometry.  The analysis revealed 305 proteins isoforms that were enriched during 
forced expression of CD151 compared to controls, including integrins α3, α6 and β1 and 
known CD151 binding partners CD9 and CD81 (Data not shown). Among the most 
enriched proteins were integrin α7, another laminin-binding integrin previously shown to 
associate with CD151 (Sterk, 2002 43), Nestin, a neuroprogenitor marker {Gilyarov, 
2008), and Isocitrate dehydrogenase 1, a protein that is typically mutated in low grade 
gliomas and glioblastoma with oligodendroglial component (Ha, 2013; Cohen, 2013). 
This suggests that CD151 may interact with other proteins in order to modulate GSC 
behavior.   
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Figure 5.8. CD151 regulates neurosphere cell self-renewal, migration and Akt 
activation by complexing with integrins. (A) GBM1A neurosphere cells collected by 
cytospin were co-immunostained with antibodies against CD151 and either integrin α3, 
integrin α6 or integrin β1 (bar = 10μm). CD151 distribution overlaps with the integrins. 
(B) GBM1A 3F-CD151 cells were treated ± Dox for 48 hours. Brij-O1 collected protein 
lysates subjected to immunoprecipitation with anti-FLAG or control IgG antibodies 
specifically precipitated 3F-CD151, Integrin α3, Integrin α6 and integrin β1 proteins. (C) 
GBM neurosphere lines GBM1A and GBM1B were transduced with lentivirus coding for 
control shRNA, CD151 shRNA 1 or CD151 shRNA 2. Total cell lysates were extracted 
and analyzed by immunoblot using antibodies against phosphorylated Akt (pAkt) and 
total Akt (tAKT). CD151 inhibition decreases expression of phosphorylated Akt. (D) 
GBM1A 3F-CD151 and GBM1B 3F-CD151 neurospheres were treated ± Dox. Whole 
cell extracts were analyzed by immunoblot for phosphorylated Akt and total Akt. CD151 
overexpression promotes phosphorylation of Akt. (E-G) GBM1A and GBM1B cells were 
treated with anti-CD151 antibody TS151r, which blocks integrin α3 binding. Isotype IgG 
was used as control. (E) Equal numbers of viable cells were cultured in 48-well plates 
with antibody for 14 days to form neurospheres. Neurospheres (>50 μm diameter) were 
counted. Neurosphere formation was inhibited by TS151r. (F) Cells were plated on 
laminin-coated transwell membranes. Migration was evaluated 8 hours later by counting 
DAPI-stained cells. Cells per field were counted. TS151r inhibited migration on laminin. 
(G)  Whole cell lysates were collected and subjected to immunoblot analysis for 
phosphorylated Akt and total Akt. CD151 knockdown inhibits Akt phosphorylation. 








Cancer cells are highly plastic in their ability to shift between more differentiated and 
more stem-like states. This phenotypic plasticity is dynamically controlled by  transcription factor 
networks that regulate cell multipotency, differentiation, and tumor propagating capacity (Y. Li & 
Laterra, 2012). Identification of these regulatory networks is paramount to understanding cancer 
cell hierarchy, malignant progression and mechanisms of therapeutic resistance.  
We previously reported that the KLF9 transcription factor inhibits glioma cell stemness 
(Ying et al., 2011). Induction of KLF9 was found to promote glioma cell differentiation and 
inhibit the expression of cell markers and drivers of stemness and the aggressiveness of 
orthotopic tumor xenografts based on multiple endpoints. These include inhibition of sphere-
forming capacity, reduced expression of cell surface CD133, BMI1, Nestin, Sox2 and Olig2, 
increased expression of neural and astroglial differentiation markers, and decreased tumor 
xenograft growth and invasiveness . The inhibitory effect of KLF9 on stemness diverges from the 
stemness-supporting effects of other KLFs, such as KLF2, 4 and 5 (Boyer et al., 2005; Jiang et 
al., 2008; J. Wang et al., 2006). The molecular mechanism underlying KLF9’s function in GSCs 
has not been extensively examined. 
This current study establishes for the first time a genome-wide map of KLF9-regulated 
targets in a human cancer stem cell model. 31,261 genome-wide KLF9 binding peaks were 
identified in GBM neurosphere cells under biological conditions of KLF9-induced stemness 
inhibition.   Amongst these peaks, 1,849 gene targets were found to be directly downregulated by 
KLF9. The predictive value of these datasets is supported by our validation of KLF9-regulated 
gene expression and KLF9 binding sites in gene subsets by qPCR and ChIP-PCR, respectively. 
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The majority of KLF9 binding sites were found to be located in intergenic regions and introns, 
and KLF9 binding peaks were found to be most enriched proximal to the TSS, patterns that 
support the gene expression regulatory function for KLF9. Statistical analyses of the differentially 
expressed genes bound by KLF9 proximal to TSS showed that KLF9 functions primarily as a 
transcriptional repressor in the context of glioma neurospheres. This does not absolutely rule out 
the possibility that KLF9 has some transactivating activity under other biological contexts, 
particularly given the strong influence of biological context and genetic background on the gene 
regulatory activities including those of KLF family members (McConnell & Yang, 2010; 
Tetreault, Yang, & Katz, 2013).  One particularly relevant example is the findings of Mitchell and 
DiMario (2010) who found in human myoblasts that KLF9 transactivated an FGFR1 promoter-
reporter construct driven by a 3,284 bp DNA sequence upstream from the FGFR1 TSS and that 
the same reporter was repressed in differentiated myotubes; however the capacity for these 
reporters to accurately mirror the regulation of endogenous FGFR1 expression in these same 
models was not addressed.  
This is the first application of genome-wide de novo motif discovery to define the KLF9 
binding DNA consensus sequence, 5’ G/A G/T GGG C/T G G/T GGCN 3’. This result is 
consistent with a previous report showing that KLF9 (also known as BTEB1) binds to a GC-rich 
DNA sequence (Imataka et al., 1992). We also confirmed the similarity of this KLF9 binding 
motif to the motifs of SP/KLF family members such as Sp1 and KLF4. KLF2, KLF4 and KLF5, 
KLFs that maintain the self-renewal of ES cells, extensively colocalized to specific genomic 
regions (Jiang et al., 2008). These and other SP/KLF family members share DNA binding motifs 
by virtue of highly conserved zinc-finger DNA-binding domains located in the carboxy terminal 
(Pearson et al., 2008). The activating or repressing transcriptional effects of KLF family members 
can be attributed at least in part to their divergent amino terminal domains that determine 
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complex formation with other transcriptional co-regulators (Pearson et al., 2008). Within this 
context, it is particularly interesting that KLF4 promotes epithelial cell stemness and 
transformation via a mechanism involving direct Notch1 transactivation (Z. Liu et al., 2009) in 
contrast to the stemness-inhibiting and direct Notch1 repressing effects of KLF9 in glioblastoma 
(Ying et al., 2011). Considerably more information regarding SP/KLF family member-specific 
transcriptional co-regulators and their context-dependent activities is needed to fully understand 
mechanisms behind the collaborative or competitive interplay among SP/KLF family members 
and the effects of this transcriptional network on cell stemness and malignancy.  
Gene function annotation and pathway analyses revealed that signaling pathways relevant 
to cancer signaling, stem cell regulation and neural cell function are enriched in KLF9 
downregulated gene targets.  Signaling pathways CXCR4 and Notch, which regulate malignancy 
and stem cell biology, were among those significantly downregulated by KLF9. CXCR4 is a 
chemokine receptor with multiple functions including the regulation of stem cell and neuronal 
cell homing and cancer cell migration (Liekens, Schols, & Hatse, 2010; R. J. Miller, Banisadr, & 
Bhattacharyya, 2008). CXCR4 signaling is active in over 20 human tumors, including gliomas 
and contributes to tumor promotion in multiple ways (Ehtesham et al., 2013; Liekens et al., 
2010). CXCR4 is highly expressed in GSCs (Ping et al., 2011) and was recently reported to 
facilitate the recruitment of GSC-derived pericytes to CXCL12-positive endothelial cells to 
support the tumor vasculature and tumor growth (Cheng et al., 2013). In addition to our novel 
findings with KLF9, several other KLFs have been reported to regulate CXCR4 expression in 
cancer cells. KLF2 downregulates CXCR4 in oral cancer cells (D. Uchida et al., 2009), while 
KLF5 has been shown to upregulate CXCR4 in prostate cancer (Frigo et al., 2009). Notch 
signaling has a prominent role in maintaining stem cell phenotypes within a variety of 
developmental and neoplastic contexts (e.g. neural stem cells, mammary stem cells, leukemia, 
121 
 
glioblastoma and mammary carcinoma) by promoting self-renewal and inhibiting differentiating 
programs (Farnie & Clarke, 2007; Kanamori et al., 2007; Weng et al., 2004). Our current finding 
that KLF9 represses multiple Notch pathway components further supports our earlier discovery 
that KLF9 inhibits GBM cell stemness , in part, by directly repressing Notch1 expression and 
downstream signaling (Ying et al., 2011). We now broaden these earlier findings by showing that 
KLF9 also downregulates NUMBL, a component of the Notch signaling pathway (L. Liu, 
Lanner, Lendahl, & Das, 2011). Evidence supports a regulatory role for NUMBL in cell 
stemness. For example, NUMBL increases expression of ES pluripotency markers by synergizing 
with Shh signaling (L. Liu et al., 2011).  
Integrin pathway members including ITGA6, ITGA9, ARPC1B, CAPN5, GIT1 and MYLK 
were also found to be enriched for KLF9-regulated gene targets. Integrin signaling modulates 
various cellular processes, such as proliferation, migration and differentiation, through cell-cell 
and cell-matrix interactions (Barczyk, Carracedo, & Gullberg, 2010). Integrins,  a family of cell 
adhesion receptors, are upregulated in stem cells and believed to support cell stemness by 
mediating adhesive interactions with stem cell niches (S. Chen et al., 2013).  Integrin α6, a 
subunit for two laminin receptors, is also highly expressed in several types of stem cells, 
including subventricular neural stem cells (NSCs) (Qian, Tryggvason, Jacobsen, & Ekblom, 
2006; Staquicini et al., 2009) and facilitates NSC adherence to endothelial cells in the 
perivascular niche (Staquicini et al., 2009). Integrin α6 has also been identified as a marker for 
cancer stem cells including GSCs (Lathia et al., 2010; Shinohara et al., 1999). It has been 
proposed that integrin α6 is essential for the maintenance of GSC self-renewal and tumor-
initiating cell phenotype providing a potential target for anti-GBM therapies (Lathia et al., 2010). 
Despite the involvement of integrin α6 in stem cell maintenance, little was known about the 
mechanisms that regulate its expression in cancer cells or how it regulates stem cell phenotypes.  
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We present the novel findings that KLF9 represses integrin α6 expression, a 
transcriptional response that in turn inhibits GBM cell stemness. Multiple complementary criteria 
were used to show that KLF9 induction inhibits integrin α6 expression by directly repressing 
ITGA6 promoter activity. These include reductions in integrin α6 mRNA and protein, and KLF9 
binding to the ITGA6 promoter.  The biological relevance of integrin α6 repression by KLF9 is 
supported by the concurrent inhibition of laminin-dependent GBM neurosphere cell adhesion, cell 
migration, and cell stemness in response to KLF9 induction and their normalization by enforced 
integrin α6 expression. The capacity for forced integrin α6 expression to reverse the inhibition of 
stem cell marker expression by KLF9 shows that KLF9 also regulates stemness in part by 
downregulating integrin α6 expression. GBM is a very hypervascular neoplasm and integrin α6-
expressing GSCs preferentially localize to the perivascular niche that serves as a source of trophic 
signals and adhesive matrix proteins, including laminin, to promote tumor cell stemness 
(Filatova, Acker, & Garvalov, 2013). Lathia et al. (2010) found that silencing integrin α6 reduces 
the self-renewal and tumor-propagating capacity of GSCs consistent with this trophic interaction.  
Further investigation into KLF9’s effects on the interaction between GSCs and perivascular niche 
could provide further insight into the mechanisms behind KLF9’s inhibitory role in GSC 
stemness and tumor suppression. 
A limitation of this study is that pathway analysis was only conducted with 
downregulated targets. Although statistical analyses suggest that KLF9 functions primarily as a 
transcriptional repressor, this does not rule out the possibility that some of the upregulated genes 
directly bound by KLF9 are true KLF9 targets. Future studies validating KLF9’s regulation of 
upregulated gene targets and identifying pathways upregulated during its overexpression in GBM 
neurospheres may provide a more accurate map of the transcriptional network regulated by KLF9 
in GSCs.  Another potential limitation is that we only examined the influence of forced integrin 
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α6 expression on GSC behavior. Because forced expression could potentially create a 
physiologically irrelevant environment that could induce activation of unrelated signaling 
pathways and cell activities, the addition of studies examining the inhibition of integrin α6 
expression on GSC behavior may provide a more comprehensive view of the influence of integrin 
α6 expression on GSC behavior. 
 Expression of the gene encoding CD151, an integrin α6 binding partner and facilitator of 
integrin signaling, is also directly downregulated by KLF9. In the present study, we present the 
novel findings that KLF9 represses CD151 expression and identifies CD151 and its direct 
interactions with integrins as novel regulators of GSC stemness and tumorigenicity. Our multiple 
approaches revealed that CD151 associates with and actively regulates GBM cell stemness. 
Glioma neurosphere cells expressing the stemness marker CD133 were found to express high 
levels of CD151 compared to CD133-negative cells and silencing CD151 blocked glioma cell 
capacity to self-renew as spheres, impaired proliferation and inhibited expression of markers and 
drivers of cell stemness including CD133, Sox2 and Olig2.   Alternatively, forcing the expression 
of the Oct4 and Sox2 transcription factors under conditions that induce glioma-propagating cells 
and CD133-positive cells (Lopez-Bertoni et al., 2014) increased expression of CD151; conversely 
forcing the expression of CD151 enhanced glioma cell self-renewal and increased expression of 
stemness-associated factors. These findings demonstrate a strong mechanistic link between 
CD151 expression and GSC stemness and provide a novel functional context to our recent report 
showing that CD151 resides within a transcriptional network that is repressed by KLF9, a 
transcription factor that induces GSC differentiation and inhibits GSC tumor-propagating 
potential. Our data is supported by previous studies from other investigators in different organ 
systems showing the association of CD151 expression with the capacity of prostate cancer cells to 
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self-renew as spheres (Rajasekhar et al., 2011) and the CD151-dependent regulation of progenitor 
cell pools during mammary development (Yin et al., 2014).  
Our results point to a role for integrins in the mechanism by which CD151 regulates 
GSCs. Laminin-binding integrin receptor subunits (integrin α3, α6, β1, β4) in particular have 
been shown to support GSC stemness. Integrin α3 is upregulated in GSCs and contributes to GSC 
migration and invasion (Nakada et al., 2013). Integrin α6 has been found to mark GSCs and 
regulate GSC self-renewal and tumor-initiating capacity (Lathia et al., 2010).We now show that 
CD151 directly complexes with integrin receptor subunits α3, α6 and β1 in GBM neurosphere 
cells and that cell responses activated by forced CD151 expression (i.e. self-renewal as spheres 
and Akt activation) are inhibited by blocking the CD151-integrin interaction. These findings 
complement previous studies in other cell models showing that CD151 forms tight complexes 
with laminin-binding integrins and influences activation of downstream integrin signaling (Hong 
et al., 2012; Kazarov et al., 2002; Sincock et al., 1999a; Sterk et al., 2002; Yauch et al., 2000).  
For example, CD151’s interaction with integrins α3 and α6 are maintained under stringent lysis 
conditions (Triton X-100 or NP-40) in melanoma, hepatocellular carcinoma and endothelial cells 
(Fei et al., 2012; Hong et al., 2012; W. F. Liu et al., 2011). W. F. Liu et al. (2011) also showed 
that overexpression of CD151 activates several downstream proteins in the integrin signaling 
pathway including FAK, PI3K, Akt, ERK1/2, cdc42 and Rac1 in endothelial cells. Because 
CD151 and ITGA6 are both downregulated by KLF9, both genes reside within a transcriptional 
network that regulates GSC stemness and glioma propagation. 
 A limitation of this study is that it does not extensively explore the involvement of other 
CD151 interactions in GSC regulation. Because CD151 participates in several interactions at the 
cell surface in tetraspanin-enriched microdomains, it is possible that CD151 influences several 
signaling pathways in order to regulate GBM cell stemness. Our preliminary proteomics analysis 
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identified 305 other proteins that CD151 may interact with in GSCs. Future studies examining the 
influence of the interaction between CD151 and these proteins on GSC behavior would help tease 
out the mechanism by which CD151 regulates these cells. 
A prominent feature of clinical gliomas and GSCs is their capacity to invade surrounding 
brain (Sever & Brugge, 2015), and CD151 has been shown to promote the adhesion and 
migratory capacity of several cancer cell types (Devbhandari et al., 2011; Fei et al., 2012; Klosek 
et al., 2005; Winterwood et al., 2006; X. H. Yang et al., 2008). We now show that CD151 
stimulates GBM neurosphere cell migration and the rate of neurosphere cell adhesion to integrin-
binding substrata. Our data showing that blocking CD151 binding to integrins α3 and α6 inhibits 
neurosphere cell migration on laminin complements the findings of Fei et al. (2012) who found 
that transfecting hepatocellular carcinoma cells with pAAV-CD151-AAA, which codes for a 
mutant CD151 deficient in integrin-binding capacity, inhibits invasion. Similarly, pAAV-CD151-
AAA has been shown to inhibit CD151 promoted cell migration in prostate cancer cells (W. Yang 
et al., 2012).   
Our finding that CD151 expression knock-down inhibits the growth of neurosphere-
derived GBM xenografts supports the translational potential of targeting CD151 and/or CD151-
integrin interactions in malignant glioma. CD151 silencing also increased tumor cell apoptosis, 
identifying CD151 as a GBM cell survival factor in vivo. It is possible that this apoptosis 
response reflects the effect of CD151 inhibition on AKT activation, a known driver of cancer cell 
survival (Sever & Brugge, 2015). Interestingly, we found that GBM neurosphere cell viability is 
not significantly affected by CD151 knockdown in vitro, suggesting that interactions between 
CD151 and elements specific to the in vivo tumor microenvironment support GSC-derived tumor 
cell survival. The tumor vasculature may represent one such element since CD151 silencing also 
reduced tumor vascular density, a response that may deprive tumors of their perivascular stem 
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cell niche and thereby reduce GBM cell viability and inhibit tumor formation. This 
antiangiogenic response mirrors previous studies showing that Lewis lung carcinoma xenografts 
display reduced angiogenic potential when established in CD151-null mice (Y. Takeda et al., 
2007).  
In conclusion, we have identified gene targets directly regulated by KLF9 on a genome-
wide scale in GBM-derived neurosphere cultures. In this GBM-derived CSC model, we show that 
KLF9 inhibits GBM cell stemness and functions predominantly as a transcriptional repressor 
within this context. KLF9 is shown to regulate multiple signaling pathways including those 
involved in oncogenesis, stem cell regulation, neuronal cell signaling, and integrin signaling. 
KLF9 is shown to inhibit GBM cell stemness and tumorigenicity, in part, by directly repressing 
integrin α6 expression and potentially through downregulation of its binding partner CD151. 
CD151 supports GBM cell stemness and self- renewal, and inhibiting CD151 expression in vivo 
induces GBM cell apoptosis, inhibits GBM angiogenesis and inhibits GBM xenograft growth. 
CD151 binding to integrins α3 and α6 and CD151-integrin complex-dependent Akt activation are 
implicated in CD151’s oncogenic activities. Our findings contribute to the understanding of the 
transcriptional networks underlying cancer stem cell maintenance and differentiation, and provide 
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